<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250326</date><key>collection.key</key><document><id>5453669</id><infon key="license">author_manuscript</infon><passage><infon key="article-id_doi">10.1530/JME-15-0283</infon><infon key="article-id_manuscript">NIHMS859211</infon><infon key="article-id_pmc">5453669</infon><infon key="article-id_pmid">26862156</infon><infon key="fpage">273</infon><infon key="issue">3</infon><infon key="kwd">cardiac hypertrophy thyroid hormone thyroid receptor alpha ubiquitin ubiquitin ligase</infon><infon key="license">
          This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.
        </infon><infon key="lpage">290</infon><infon key="name_0">surname:Wadosky;given-names:Kristine M</infon><infon key="name_1">surname:Berthiaume;given-names:Jessica M</infon><infon key="name_2">surname:Tang;given-names:Wei</infon><infon key="name_3">surname:Zungu;given-names:Makhosi</infon><infon key="name_4">surname:Portman;given-names:Michael A</infon><infon key="name_5">surname:Gerdes;given-names:A Martin</infon><infon key="name_6">surname:Willis;given-names:Monte S</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">56</infon><infon key="year">2017</infon><offset>0</offset><text>MuRF1 mono-ubiquitinates TRalpha to inhibit T3-induced cardiac hypertrophy in vivo</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>83</offset><text>Thyroid hormone (TH) is recognized for its role in cellular metabolism and growth and participates in homeostasis of the heart. T3 activates pro-survival pathways including Akt and mTOR. Treatment with T3 after myocardial infarction is cardioprotective and promotes elements of physiological hypertrophic response after cardiac injury. Although T3 is known to benefit the heart, very little about its regulation at the molecular level has been described to date. The ubiquitin proteasome system (UPS) regulates nuclear hormone receptors such as estrogen, progesterone, androgen, and glucocorticoid receptors by both degradatory and non-degradatory mechanisms. However, how the UPS regulates T3-mediated activity is not well understood. In this study, we aim to determine the role of the muscle-specific ubiquitin ligase muscle ring finger-1 (MuRF1) in regulating T3-induced cardiomyocyte growth. An increase in MuRF1 expression inhibits T3-induced physiological cardiac hypertrophy, whereas a decrease in MuRF1 expression enhances T3's activity both in vitro and in cardiomyocytes in vivo. MuRF1 interacts directly with TRalpha to inhibit its activity by posttranslational ubiquitination in a non-canonical manner. We then demonstrated that a nuclear localization apparatus that regulates/inhibits nuclear receptors by sequestering them within a subcompartment of the nucleus was necessary for MuRF1 to inhibit T3 activity. This work implicates a novel mechanism that enhances the beneficial T3 activity specifically within the heart, thereby offering a potential target to enhance cardiac T3 activity in an organ-specific manner.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1714</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1727</offset><text>Thyroid hormone (TH) is recognized for its role in cellular metabolism and growth and participates in homeostasis of the heart. Its biologically active form (T3) is involved in directing myocyte alignment and geometry, extracellular matrix remodeling, and cardiac function through the effects on contraction. T3 mediates both direct influences on cardiac function by affecting calcium flux and calcium handling proteins, in addition to voltage-gated potassium channels to affect contractility, and through transcriptional regulation as TH is a ligand for the thyroid hormone receptor, predominantly the alpha isoform, TRalpha in the heart. A decrease in TH concentrations has been observed in acute myocardial infarction, and low circulating TH is commonly observed with severe heart failure (HF). Treatment with TH following myocardial infarction is cardioprotective and promotes elements of physiological hypertrophic response after cardiac injury. T3 activates many of the physiological changes that would benefit the heart, activating pro-survival pathways Akt and mTOR and paralleling changes induced by exercise-mediated by IGF-1. Despite our rich knowledge of the cardioprotective effects of T3, little is known about the intracellular regulation of its action.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2996</offset><text>Intracellular regulation of nuclear receptors by posttranslational modification by ubiquitin is well known and involves two distinct mechanisms: 1) targeted degradation of nuclear receptors by the proteasome and 2) ubiquitination-altering activity in non-degradatory ways. For example, estrogen, progesterone, androgen, and glucocorticoid nuclear receptors are degraded in a proteasome-dependent manner in some conditions, with their heterodimeric binding partners RARgamma and RXR also degraded by parallel mechanisms. The muscle-specific ubiquitin ligase MuRF1 has recently been shown to specifically inhibit PPARalpha, but not PPARbeta/delta or PPARgamma1, activity in vivo. In contrast to the previous studies on nuclear receptors, MuRF1 was found to inhibit PPARalpha in the cardiomyocyte through mono-ubiquitination that enhanced nuclear export without promoting PPARalpha degradation. By mono-ubiquitinating one to three lysines adjacent to a newly identified nuclear export sequence in PPARalpha, MuRF1 inhibited PPARalpha-regulated fatty acid oxidation both in vitro and in vivo. Complementary to these studies, the closely related muscle-specific ubiquitin ligase MuRF2 inhibited PPARgamma1, whereas MuRF3 inhibited PPARbeta activity in vivo by mono-ubiquitination. In this study, we identify the cardiac ubiquitin ligase MuRF1 as an inhibitor of T3-induced physiological cardiac hypertrophy in vivo. We determined that MuRF1 directly interacts with a specific thyroid receptor to mediate its posttranslational modification and inhibit its activity. These studies then determined a previously undescribed mechanism in which MuRF1 inhibits T3 activity, by altering TRalpha localization via posttranslational ubiquitination.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4729</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4751</offset><text>Preparation of T3 and free T3 concentration estimates</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4805</offset><text>3,3',5-Tri-iodo-l-thyronine (T3, #T2877; Sigma-Aldrich) was weighed (0.003 g) on an analytical scale, dissolved in 20 ml sterile PBS, heated at 37 C for 10 min, and vortexed at the highest setting for 1 min. As a percentage of T3 remains insoluble using this method, we determined the resulting free T3 of this preparation compared with alkalizing T3 with 1 N NaOH (1 mL per mg) and putting in PBS, as described by the manufacturer. Analysis of free T3 heated/vortexed vs NaOH solubilized was made on the Vitros 5600 chemistry analyzer (Ortho Clinical Diagnostics, Rochester, NY, USA) in a matrix-compatible diluent to a final concentration of 50 ng/mL. With NaOH solubilization and dilution in PBS, 52.3 +- 8.4 ng/mL (N = 3) was recovered compared with 0.87 +- 0.012 ng/mL (N = 3). The recovery ratio (60.4 = 52.3/0.87) was used to estimate the concentrations of T3 in all the experiments described in vitro and in vivo.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5730</offset><text>Culturing of neonatal rat ventricular myocytes (NRVM), HL-1 cells, and in vitro experimental design</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5830</offset><text>NRVMs were isolated using a commercial kit according to the manufacturer's protocols, as described previously (#LK003300; Worthington Biochemical Corporation, Lakewood, NJ, USA). NRVMs cultured on fibronectin with medium 199 (M199) supplemented with 15% FBS were serum starved, transduced with plasmids, and treated with 16.6 nM T3. The cardiac-derived HL-1 cell line was maintained as described previously. COS-7 cells were cultured using the supplier's protocols (CRL-1651, ATCC; Manassas, VA, USA). myc-tagged MuRF1/bicistronic GFP adenovirus (AdMuRF1), GFP adenovirus control, AdshRNA-MuRF1 (shMuRF1), or a control vector with scrambled AdshRNA (CTL) was used as described previously. Cells were transduced with 25-60 MOI for 24-48 h and incubated with T3 in serum-free DMEM. Cellular fractionation was carried out using the Nuclear Extraction Kit (#AY2002, Panomics, Fremont, CA, USA) according to the manufacturer's protocol.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6772</offset><text>CAP350 silencing and size measurement of HL-1 cells</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6824</offset><text>HL-1 cells were treated with Accell mouse CAP350 (centrosome-associated protein 350) siRNA (GE Healthcare) using 1 muM Accell siRNA as per the manufacturer's delivery protocol. Size measurement off HL-1 cells was performed using Image J.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7064</offset><text>TRalpha-mediated thyroid response element (TRE)-driven luciferase activity assay</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7145</offset><text>Cos-7 cells were co-transfected with plasmids expressing beta-galactosidase, growth hormone TRE luciferase reporter, as described previously, and the p3XFLAG-CMV-14 (Sigma-Aldrich) either empty or with the murine TRalpha sequence subcloned into the vector at the EcoRI and BamHI restriction sites.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7443</offset><text>Cell immunoblot analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7468</offset><text>Cells were lysed in Cell Lysis Buffer (Cell Signaling), supplemented with protease (#11697498001; Roche) and phosphatase inhibitors (#04906845001; Roche), in addition to 0.2 M glycerol-2-phosphate (Sigma-Aldrich) and resolved on NuPAGE gels (Novex; Life Technologies). Primary antibodies used in this study are beta-actin (1:10,000, Cat. #A5441; Sigma-Aldrich), CAP350 (1:1000, Cat. #20022-1-AP; Acris Antibodies, San Diego, CA, USA), FLAG-TRalpha (1:1000, anti-FLAG #F7425; Sigma-Aldrich), GAPDH (1:10,000, Cat. #G8795; Sigma-Aldrich), MuRF1 (1:250-1:1000, #AF5366; R&amp;D Systems), GAPDH (1:4000, G8795; Sigma-Aldrich), p-Rb (#sc-50; Santa Cruz Biotechnology), myc-tagged MuRF1 (1:4000, anti-myc, #C4439; or anti-myc-HRP-linked primary, 1:10,000, #A5598; Sigma-Aldrich), glutathione-S-transferase (GST)-tagged TRalpha (anti-GST; #G1160; Sigma-Aldrich, 1:10,000), TRalpha (PA1-211A; Thermo Scientific, 1:500), and HA-ubiquitin (anti-HA; #sc-57592, 1:1000). HRP-linked secondary antibodies used in this study are anti-mouse (#NA931V; GE Healthcare Life Sciences, 1:10,000), anti-rabbit (#A9169, Sigma-Aldrich, 1:20,000), and anti-goat (#A5420; Sigma-Aldrich, 1:10,000).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8635</offset><text>Constructs for confocal TRalpha lysine domain mutants and GST-TRalpha mapping i.p. studies</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8726</offset><text>DNA constructs for the full sequence of TRalpha1 containing modification of all lysine codons to encode arginine (K R) were synthesized for each domain separately (A/B, C, D, and E/F: Supplementary Fig. S2 (see section on supplementary data given at the end of this article)) and subcloned into the p3xFLAG-CMV-14 expression vector, sequence verified, and transfected into cells.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9106</offset><text>Confocal immunofluorescence analysis and co-localization analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9172</offset><text>Cells grown on Flexcell plates (Flexcell International, Hillsborough, NC) were transfected with plasmids indicated, transduced (AdGFP or AdMuRF1), and treated with 16.6 nM T3 (or vehicle) for 2 h. Cells were fixed in 4% formaldehyde, sectioned, and blocked in 0.4% Triton X-100/5% FBS. Primary antibodies were applied overnight followed by incubation with secondary antibodies. After washing, fixed cells were mounted onto glass slides with Fluoro-Gel II Mounting Media containing DAPI (17985-50; Electron Microscopy Services, Hatfield, PA, USA). A Leica DMIRB inverted fluorescence microscope (Leica Microsystems, Buffalo Grove, IL, USA) with a 40x objective lens and with a 10x Hamamatsu Orca ER camera (Bridgewater, NJ, USA) was used to analyze cell size.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9933</offset><text>Co-localization analysis was performed by determining the coefficient values representing the degree in which two different fluorescence channels (450, 488, 568, or 647) overlap in isolated regions of the cardiomyocyte using Volocity 3D Images Software Quantitation (PerkinElmer). For TRalpha and nuclear co-localization, for every cell in each image, the nuclear region of the cell was selected by tracing around the DAPI fluorescent signal. Then, quantitative co-localization analysis within the selected region was analyzed between 450 (DAPI) and 568 (TRalpha). Measurements were made using the Costes' Pearson's coefficient correlation statistics function provided within the software that uses the threshold values for each channel to adjust the final coefficient data. For correlation coefficients, numeric range is from 0 to 1, where 0 indicates no correlation and 1 indicates perfect correlation. For at least 20 cells per condition in at least three images, correlation coefficients were averaged and final data were presented as the average +- SE.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10991</offset><text>Co-immunoprecipitation</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11014</offset><text>Transduced Cos-7 cells (AdGFP or AdMuRF1) treated with T3 (or vehicle) were lysed in buffer (50 mM Tris, pH 7.5, 30 mM NaCl, 1 mM EDTA, and 0.5% (v/v) Triton X-100) supplemented with 2x protease inhibitor cocktail (Roche) and 1x phosphatase inhibitor cocktail (Roche), then pre-cleared with 5 mug rabbit IgG (I5006; Sigma-Aldrich) and 2% (v/v) Protein A/G PLUS Agarose beads (sc-2003; Santa Cruz Biotechnology) per 1 mg of protein lysate for 1 hour at 4 C with rotation. Myc-MuRF1 was immunoprecipitated using 5% (v/v) EZ View Red Anti-c-Myc Affinity Gel (E6654; Sigma-Aldrich) by incubating with anti-c-myc beads overnight at 4C with rotation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11662</offset><text>GST pull down</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11676</offset><text>Recombinant GST-TRalpha-mapping constructs were produced using BL21-CodonPlus Competent Cells transduced with pGEX-KG-TRalpha domain plasmids using standard protocols (Stratagene, La Jolla, CA, USA). Isolation of GST-tagged recombinant proteins was carried out using the BugBuster GST-Bind Purification Kit (70794-3; EMD Millipore Novagen, San Diego, CA, USA) according to the manufacturer's protocol; the glutathione column with GST protein was then incubated with 1 mg protein lysate from Cos-7 cells transduced with AdMuRF1 overnight at 4C with rotation, allowing MuRF1 to bind TRalpha domains. Unbound proteins were then collected and elution steps were carried out according to the manufacturer's protocol. Unbound and eluate fractions were immunoblotted for GST-tagged recombinant TRalpha (anti-GST (#G1160), 1:10,000; Sigma Aldrich) and myc-tagged MuRF1 (anti-myc (#C4439), 1:4000; Sigma Aldrich).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>12581</offset><text>Cell-free ubiquitination assay</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12612</offset><text>To evaluate direct ubiquitination of TRalpha by MuRF1, human recombinant E1 (50 nM, Cat. #E-305; Boston, Biochem, Cambridge, MA, USA), human recombinant UbcH5c/UBE2D3 (2.5 mM, Cat. #E2-627; Boston Biochem, Inc., Cambridge, MA), human recombinant ubiquitin (250 muM, Cat. #U-100 H; Boston Biochem), human recombinant his-6-MuRF1 protein (1 mg, Cat. #E3-100; Boston Biochem), and human TRalpha recombinant protein (500 ng; Abnova, Walnut, CA, USA) were added to the reaction buffer (50 mM HEPES, pH 7.5) containing 5 mM MgATP solution (Boston Biochem) and 0.6 mM DTT and were incubated overnight at 30 C. The reaction was stopped by SDS-PAGE sample buffer and heating, then resolved on a 4-12% Bis-Tris gel with MOPS running buffer (Invitrogen), and transferred to PVDF membranes for immunoblotting with rabbit polyclonal anti-TRalpha antibody (Thermo Scientific Pierce, Inc., Rockford, IL, USA) or rabbit polyclonal anti-MuRF1 antibody (R&amp;D Systems).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>13562</offset><text>Animals, treatment with T3, conscious echocardiography</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13617</offset><text>Male and female adult mice (8-16 weeks) from a knockout (MuRF1-/-) and a cardiomyocyte-specific MuRF1 transgenic (alphaMHC promoter driven) mouse (MuRF1Tg+) with strain-matched wild-type mice (MuRF1+/+ or wild type MuRF1Tg+ respectively) were used as described previously. Randomly assigned mice were treated with 16.6 mug/kg/day 3,3',5-tri-iodo-l-thyronine (T3, #T2877; Sigma-Aldrich) dissolved in sterile PBS or PBS as a vehicle control via intraperitoneal injection (i.p.) for 2 weeks. Conscious echocardiographic analysis was performed at baseline, 1 week, and 2 weeks. After 2 weeks, mice were anesthetized to collect retro-orbital blood and then killed for tissue harvest. Hearts were quickly excised and frozen in liquid nitrogen and then stored at -80 C.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14388</offset><text>Histological analysis of mouse hearts</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14426</offset><text>Fixed cardiac tissue was paraffin embedded, processed, sectioned, and stained with hematoxylin and eosin or Masson's trichrome. Stained slides were scanned using an AperioScanscope and images were exported using AperioImagescope software (Aperio Technologies, Vista, CA, USA). Cardiomyocyte cross-sectional area was determined on MT-stained slides using ImageJ software (NIH, MD, USA) on a minimum of six randomly selected regions per image (100x magnification) from three different hearts per group.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14930</offset><text>Analysis of T3 and T4 in serum</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14961</offset><text>T3 and T4 was quantitated in serum using the Luminex MAGPIX system (EMD Millipore) with the MILLIPLEX MAP magnetic bead-based Multi-Species Steroid/Thyroid Hormone assay (Cat. #STTHMAG-21 K) analyzed on the MAGPIX Multiplexing instrument (Life Technologies).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15220</offset><text>Tissue immunoblot analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15247</offset><text>Mouse heart tissue was lysed in 8 M urea buffer and stored at -80 C. Antibodies recognizing Rb (Cat. #MA5-11387) and p-Rb (Cat. #MA5-12584) were obtained from Life Technologies (Carlsbad, CA, USA) and were used at 1:200 dilution. Antibody recognizing TRalpha (Cat. #PA1-211A; Thermo Scientific) and antibody recognizing GAPDH (Cat. #G8795; Sigma-Aldrich) were used at 1:200 and 1:10,000 dilutions respectively.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15660</offset><text>RT-qPCR</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15668</offset><text>Ventricular tissue (5 mg) was homogenized using the TissueLyser LT (Qiagen). Cells were homogenized by syringe and needle in TRIzol (Life Technologies, Invitrogen), and total RNA was isolated according to the manufacturer's protocols. cDNA was generated from 1 mug RNA using a High-Capacity cDNA Archive Kit (Life Technologies, Invtirogen). One microliter of cDNA product was amplified in a LightCycler 480 Sequence Detection System (Roche) in 10 mul final volume using the LightCycler 480 Probes Master Mix (Roche). The PCR reaction mix included 0.5 mul of mouse-specific 20x Taqman probes (Life Technologies, Applied Biosystems): sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) (Mm01201431_m1), MuRF1 (Mm01185221_m1), alphaMHC (Mm00440359_m1), mitochondrial adenine transporter (ANT) (Mm01207393_m1), ANF (Mm01255747_g1), BNP (Mm00435304_g1), alpha1 skeletal muscle actin (ACTA1) (Mm00808218_g1), monocarboxylate transporter 8 (MCT8) (Mm01232724_m1), or monocarboxylate transporter 10 (MCT10) (Mm00661045_m1). Tbp (Mm00446971_m1) or 18 S (Hs99999901_s1) served as reference genes. The --Ct method was used to determine the relative expression values that were normalized to the wild-type control group.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>16874</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16895</offset><text>A two-way ANOVA with the Holm-Sidak post hoc test for all pairwise comparisons was used to evaluate the statistical significance with SigmaPlot software (Systat Software, Inc., Chicago, IL, USA). In TRalpha KR domain mutant experiments, a one-way ANOVA test was applied with an all pairwise post-test. The criterion for significance was a P-value of &lt;= 0.05 (Supplementary data, see section on supplementary data given at the end of this article).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>17343</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17351</offset><text>To identify the role of MuRF1 in regulating TH-induced physiological hypertrophy, HL-1 cardiomyocyte-derived cells and neonatal rat cardiomyocytes (NRVMs) were stimulated with tri-iodothyronine (T3). As expected, T3 induced cardiomyocyte hypertrophy, reflected by increased CSA (Fig. 1A, B and C, Supplementary Fig. S1A, B and C, uncropped). T3 stimulation of cardiomyocytes with MuRF1-knockdown (using AdshMuRF1, ~50% decrease in protein, Fig. 2C) resulted in a significant increase in CSA compared with T3 alone (Fig. 1A). Conversely, increasing MuRF1 expression (AdMuRF1) significantly inhibited T3-induced increase in CSA in both HL-1 cells and NRVM (B and C). Together, these studies indicated a role of endogenous MuRF1 in attenuating T3-induced cardiac hypertrophy.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18124</offset><text>We next aim to further define how MuRF1 inhibits T3-induced cardiomyocyte hypertrophy mechanistically. We focused our attention on MuRF1's regulation of thyroid receptor (TR) TRalpha1 activity, as it is the only isoform in cardiomyocytes that stimulates growth (the less common TRalpha2, and TRbeta1 are present but lack this activity) (,). In these studies, we identified that increasing MuRF1 expression significantly inhibited TRalpha-induced TRE-luciferase activity (Fig. 2A). As another way to measure TRalpha activity, we next evaluated how increasing MuRF1 would affect TR target genes and identified that MuRF1 significantly inhibited sarco/endoplasmic reticulum Ca2+-ATPase (SERCA expression (Fig. 2B)). Other well-known TRalpha targets (alphaMHC and ANT) were not increased in these studies, which may be due to the limited 30-min T3 stimulation (Fig. 2B). As MuRF1's inhibition of TRalpha could result from poly-ubiquitination and proteasome-dependent degradation, we performed immunoblot analysis of TRalpha levels under conditions where MuRF1 inhibited its activity and found that increasing MuRF1 did not change TRalpha protein concentration (Fig. 2C). As both increasing and decreasing MuRF1 expression in T3-induced cardiomyocyte hypertrophy did not affect the steady-state levels of TRalpha (Fig. 2C), we were able to rule out MuRF1-mediated TRalpha degradation as a mechanism.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19519</offset><text>In recent studies, we demonstrated that MuRF1 inhibited PPARalpha activity similarly without affecting PPARalpha protein concentration. Using confocal microscopy, we found that increasing MuRF1 removed nuclear PPARalpha in a majority of the cells that subsequent studies found was due to MuRF1-targeted increased in nuclear export. Therefore, we next determined whether MuRF1 inhibits T3-induced TRalpha1 activity by altering TRalpha1's nuclear localization. HL-1 cardiomyocytes were transfected with TRalpha1 and/or MuRF1 (+/-T3) and analyzed by confocal microscopy. Interestingly, T3 altered the nuclear localization of TRalpha1 (Fig. 3A, column 4) compared with controls (Fig. 3A, column 3). Specifically, it appeared that MuRF1 altered TRalpha1 nuclear localization by moving it to the nuclear periphery, a region closely aligned with the endoplasmic reticulum and microtubule anchoring complexes. To confirm this localization, we first identified the co-localization of the nuclear proteins lamin beta1 and desmin with TRalpha1 using confocal immunofluorescent analysis (Fig. 4A). Increasing MuRF1 expression significantly increased the co-localization of TRalpha1 with nuclear lamin beta1 (Fig. 4), while similarly increasing the co-localization of TRalpha1 with desmin (Supplementary Fig. S2). Lastly, we assessed MuRF1's effects on TRalpha1 nuclear localization by isolating the cardiomyocyte nuclear fraction by differential centrifugation and measuring the amount of TRalpha1 by immunoblot (Fig. 4B). Together, these studies demonstrate that increasing MuRF1 sequestered TRalpha1 in the nucleus, to inhibit TRalpha1 nuclear activity.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21163</offset><text>To assess whether TRalpha is a MuRF1 substrate, we next determined whether MuRF1 interacted directly with TRalpha by transfecting cells with MuRF1 and immunoprecipitating the myc-labeled MuRF1 (Fig. 5A). To determine the specific region of TRalpha that MuRF1 interacts, we next performed a pull-down assay using recombinant TRalpha domains to identify their ability to interact with full-length MuRF1 (Fig. 5B). We found that MuRF1 binds the TRalpha hinge (or D, as denoted on the diagram) domain of the receptor (Fig. 5B, right). With evidence that MuRF1 interacts with TRalpha, we next tested MuRF1's ability to ubiquitinate TRalpha in vitro. We identified that MuRF1 catalyzes TRalpha mono-ubiquitination (Fig. 5C), a posttranslational modification that does not target substrate for degradation, consistent with our initial findings in cardiomyocytes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22019</offset><text>With evidence that MuRF1 mono-ubiquitinated TR in a cell-free system, we next aim to identify these in cells. We observed an unexpected complication of identifying MuRF1's mono-ubiquitination in cells where a strong background of TRpoly-ubiquitination occurs (Fig. 5D). As described in cancer cells, poly-ubiquitination is a common way in which thyroid hormone receptors have been described natively (Fig. 5E, as described in TRbeta). As immunoprecipitated TRalpha was polyubiquitinated in control cells (Figure 5D, red box), we hypothesized that the poly-ubiquitination competed for the sample lysines that MuRF1 mono-ubiquitinated. Support for this hypothesis came from studies with increased MuRF1 (AdMuRF1), where there was decreased poly-ubiquitination (Fig. 5D, blue box). While the identification of a mono-ubiquitinated TRalpha was not achieved, we did identify the common dichotomy competing mono- and poly-ubiquitin for substrates, known to be dependent on the types of E2 present and ratios of E3 to substrates.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23042</offset><text>The centrosome-associated protein (CAP) CAP350 has recently been identified as protein involved in regulating nuclear receptor activity, including PPAR. Initially, we analyzed MuRF1's effects on the co-localization of endogenous CAP350 and TRalpha in cardiomyocytes by confocal imaging (Fig. 6A). We found that increasing MuRF1 significantly increased nuclear CAP350 and the co-localization of CAP350 and TRalpha (Fig. 6A, right two columns). The increased co-localization of CAP350 and TRalpha driven by increasing MuRF1 was most apparent in the perinuclear region following T3 stimulation (Fig. 6A, in yellow). To solidify CAP350's mechanistic relationship to MuRF1's inhibition of TRalpha, we next knocked down CAP350 (to &lt; 50%, Fig. 6B) and determined its effect on cardiomyocyte cross-sectional area (Fig. 6C). In control cells, CAP350 knock-down attenuated the T3-induced cardiomyocyte hypertrophy (experimental group 3 vs group 2, Fig. 6C). The MuRF1 attenuation of T3-stimulated cardiomyocyte growth (experimental group 6 vs group 3, Fig. 6C) was significantly overcome (i.e increased in cross-sectional area size) with CAP350 knock-down (experimental group 5, Fig. 6C). Together, these studies demonstrate a role of CAP350 in MuRF1's regulation of TR in cardiomyocytes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24321</offset><text>We next aim to identify the region within TRalpha protein that MuRF1 ubiquitinates to modify its activity. A well-known challenge to studying protein ubiquitination is its heterogeneous nature; when a major ubiquitination site (lysine) is mutated, it is common for nearby lysines to be alternatively targeted. In practice, this means that mutating single lysines does not alter ubiquitination, even if the major site is mutated, as alternative sites are targeted. As the goal of mutating a lysine would be to prevent specific ubiquitination, we took an alternative approach and mutated lysine residues in specific regions of the TR protein. Four full-length TRalpha constructs were created with lysine residues mutated to arginine (KR) (Supplementary Fig. S3): TRalpha A/B (AF1, N-terminus), TRalpha C (DNA-binding), TRalpha D (hinge), and TRalpha E/F (ligand-binding). These TRalpha constructs were then expressed in cardiomyocytes and assessed for their response to MuRF1 alterations in localization by confocal microscopy (). Increasing MuRF1 expression localized the TRA/B, C, and D lysine mutants to the perinuclear region as observed with the native receptor (Fig. 7A). In contrast, cells expressing the E/F TR domain mutant exhibit a distinctly nuclear localization of the receptor rather than a perinuclear one as observed with the native form implying that MuRF1 ubiquitinates residues in this domain to negatively regulate TR function (Fig. 7A, far right). Interestingly, when the E/F TR domain mutant was expressed, CAP350 localization was affected, moving from a perinuclear to a pan-nuclear distribution (Fig. 7B, far right). Together, these studies illustrate that MuRF1 inhibits TRalpha activity by mono-ubiquitinating it in the E/F region, resulting in an interaction with CAP350 and nuclear sequestration in cardiomyocytes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>26162</offset><text>To determine the physiological relevance of these mechanistic findings in vivo, we next challenged MuRF1-/- and MHC-MuRF1 cardiomyocyte-specific transgenic mice (MuRF1Tg+) with daily T3 i.p. for 2 weeks. We followed the cardiac phenotype by conscious echocardiography and histological analysis. Echocardiographic and histological assessment identified that T3 induced an exaggerated cardiac hypertrophy in MuRF1-/- compared with sibling-matched wild-type controls, evidenced by increases in left ventricular anterior wall thickness and LV mass (Fig. 8A, Table 1 for full echocardiographic data) and cardiomyocyte area (Fig. 8B). Interestingly, MuRF1-/- had an enhanced systolic function, reflecting increases in contractility and reflective of the T3-induced enhancements driven by increases in SERCA and phospholamban. Overall, the MuRF1-/- mice had a 53.6% increase in cardiomyocyte area compared with the 30.5% increase found in the wild-type controls (Fig. 8B). Consistent with these findings, the MuRF1Tg+ mice challenged with T3 had an attenuated cardiac hypertrophy response in vivo (Fig. 8C). Echocardiographic and histological assessment identified that MuRF1Tg+ mice had significantly less LV anterior and posterior wall thickness compared with sibling-matched wild-type controls (Fig. 8A, Table 2 for full echocardiographic data) as well as cardiomyocyte area (Fig. 8D). Significant reductions in systolic function over time were observed (Fig. 8C), consistent with an increase in pathological hypertrophy, identified by increases in BNP, alpha1-skeletal muscle actin, and ANF (data not shown). The observed effects on TH-induced physiological hypertrophy in our mouse models were most likely attributable to MuRF1 activity as circulating concentrations of T3/T4 were not altered in MuRF1-/- or MuRF1Tg+ mice (Supplementary Fig. S5A and B). Furthermore, MCT8 and -10 expressions (transporters involved in the uptake and efflux of T3) were not significantly different across the genotypic groups (Supplementary Fig. S5C and D). All studies included parallel PBS-injected controls, with no alterations seen (as detailed in Supplementary Tables S1 and S2). Overall, these studies demonstrate that the MuRF1-/- mice exhibited an exaggerated cardiac hypertrophy, while MuRF1Tg+ hearts lacked the development of cardiac hypertrophy in response to T3, consistent with a role for MuRF1 in inhibiting TRalpha activity in vivo. With no evidence for alterations in steady-state TRalpha protein levels in vivo (Supplementary Fig. S4), like those found in vitro (Fig. 2C), cardiomyocyte MuRF1's inhibition of TRalpha is relevant in the intact heart illustrating alternative mechanisms that could be targeted to protect against heart failure in a tissue-specific manner.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>28944</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28955</offset><text>Understanding how the thyroid hormone receptor alpha is regulated is critical to our understanding of heart disease. Inhibiting TRalpha in myocardial infarction experimentally impairs post-ischemic performance due to activation of p38 and an increased phospholamban. Conversely, T3 therapy protects the heart against ischemia:reperfusion injury in a TRalpha-dependent manner. T3 also seems to counteract the maladaptive responses implicated in adrenergic induced cardiomyocyte remodeling. Stimulation of cardiomyocytes with phenylephrine results in increased fetal gene expression (betaMHC); co-stimulating cardiomyocytes with phenylephrine and T3 blocks these maladaptive changes, while increasing TRalpha expression in the nucleus and cytosol. In models of myocardial infarction (acute coronary artery ligation) leading to compensated heart failure, a distinct pattern of TRalpha expression was found during the course of post-ischemic remodeling. TRalpha was upregulated initially, then markedly decreased during the transition to decompensated heart failure, resulting in tissue hypothyroidism. While circulating T3 and T4 levels remained unchanged, a link between mTOR and TRalpha was identified. Together, these studies illustrate the critical role the TRalpha plays in heart failure and how regulating TRalpha expression can critically affect disease progression and severity.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>30339</offset><text>The regulation of nuclear hormones by the ubiquitin proteasome system occurs in a myriad of ways. Some nuclear hormone receptors are degraded in both the presence and absence of their cognate ligands, such as the estrogen, progesterone, and glucocorticoid receptors ( ). Alternatively, the androgen receptor and the PPARalpha are targeted to the proteasome in the absence of ligand. The closely related receptors that heterodimerize with PPARs, such as RARgamma and RXR, are also degraded by the ubiquitin proteasome system with fewer details available. We have recently extended these findings to demonstrate that the muscle-specific ubiquitin ligase MuRF1 specifically inhibits PPARalpha, but not PPARbeta/delta or PPARgamma1 activity in vivo. In contrast to previous studies on nuclear receptors, we identified that MuRF1 had an inhibitory effect on PPARalpha in cardiomyocytes by enhancing nuclear export, not degradation. By multi-mono-ubiquitination of lysines adjacent to the newly identified nuclear export sequence in PPARalpha, MuRF1 inhibited PPARalpha-regulated fatty acid oxidation both in vitro and in vivo. Complementary to these studies, the closely related muscle-specific ubiquitin ligase MuRF2 was found to inhibit PPARgamma1, while MuRF3 inhibits predominantly PPARbeta activity in vivo through mono-ubiquitination of substrates.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31689</offset><text>While cardiac MuRF1 has multiple roles in the heart, a consistent theme of its activity has been its anti-hypertrophic activity and regulation of metabolism. In pressure overload-induced cardiac hypertrophy, MuRF1 inhibits pathological hypertrophy by inhibiting the serum response transcription factor. In physiological hypertrophy induced by exercise (IGF-1), MuRF1 transcriptionally inhibits cardiomyocyte growth by inhibiting cJun-mediated increases in IGF-1 signaling proteins, by preferentially recognizing phospho-cJun, poly-ubiquitinating, and targeting it for proteasome-dependent degradation in vivo. Metabolically, MuRF1 has been found to ubiquitinate oxidized creatine kinase, mediating its turnover in vivo. Increasing MuRF1 decreases creatine kinase activity significantly in the intact heart, resulting in a reduction of this critical transporter of ATP from the mitochondria to the sarcomere, resulting in heart failure. MuRF1 also inhibits PPARalpha, interacts with a host of energy-related proteins, and alters the cardiac metabolome in vivo. Building upon this larger theme, this study demonstrates MuRF1's anti-hypertrophic role in T3-mediated cardiomyocyte growth, with broader implications in T3-regulated metabolic rates critical to cardiac function in health and disease.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32984</offset><text>The link between MuRF1 and the centrosome-associated protein 350 (CAP350) stems from the observation that MuRF1 alters nuclear TRalpha distribution in a similar manner as CAP350 does with PPARalpha. Although the role of CAP350 in regulating nuclear hormone receptors (such as TRalpha) is established, the mechanistic details have yet to be elucidated. In previous studies, the recently defined centrosome- and cytoskeleton-associated protein CAP350 was found to inhibit PPARalpha activity by redirecting PPARalpha's nuclear distribution to the perinuclear area with punctate distribution. In this study, we similarly observed that MuRF1 altered the nuclear distribution of TR (Fig. 3A), which led to subsequent studies to delineate the underlying mechanistic relationship between MuRF1's anti-hypertrophic activity with T3 stimulation and MuRF1's reliance upon CAP350 for preventing hypertrophic growth (Fig. 6C). The present studies illustrate that MuRF1's attenuation of T3-induced cardiomyocyte growth is dependent on TRalpha mono-ubiquitination of the ligand-binding domain (Fig. 7) and interaction with CAP350 (with significantly smaller cardiomyocytes with MuRF1 and CAP350 present, Fig. 6C, group 6). Our working hypothesis on the role of MuRF1 in this process is that MuRF1 mono-ubiquitinates TRalpha to enhance its affinity for CAP350, which sequesters TRalpha-Ub in nuclear compartments making it inaccessible to DNA promoters to diminish transcriptional activity.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>34459</offset><text>Protein mono-ubiquitination that results in an enhanced affinity to other proteins is a common molecular process noted in the biology of cancer. An established example is the ubiquitin ligase MDM2, which mediates p53 mono-ubiquitination. In this system, p53 mono-ubiquitination alters its conformation to preferentially bind CRM1 (a subunit of the nuclear export apparatus), which then enhances p53 nuclear export resulting in activity inhibition. This is an emerging, common theme, further illustrated with the estrogen receptor (ER), when the BRCA1 ubiquitin ligase mono-ubiquitinates it to inhibit its activity and the suppression of DNA polymerase Eta, when mono-ubiquitinated by the Pirh2 ubiquitin ligase. The present studies demonstrate a novel role for CAP350 activity in the heart and an emerging role in regulating TRalpha activity that has not been previously reported.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>35340</offset><text>Posttranslational modification of TRalpha by ubiquitin has not previously been described; however, its regulation by the closely related small ubiquitin-related modifier (SUMO) has been in cancer. Paralleling the ubiquitination process, SUMOylation involves the addition of a single SUMO modification, added by the cooperation of the SUMO E1, E2, and E3 (SUMO ligase) enzymes. Interestingly, SUMO modification alters cellular processes, including nuclear transport, transcriptional regulation, apoptosis, and protein stability without degrading its substrate. SUMOylated TRalpha has been reported in both liver (HepG2) and pituitary (GH3) cell lines (Liu et al.2012), mediated by the SUMO ligase PIAS1. In the absence of ligand, PIAS1 SUMOylates TRalpha, whereas the SUMO ligase PIASx SUMOylates TRbeta only in the presence of ligand. Both SUMO1 and SUMO3 (two different types of SUMO modification) have been reported in T3-dependent gene regulation, closely matching TR activity and cofactor recruitment to the TRE in ChIP assays.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>36372</offset><text>This study describes a non-canonical ubiquitination (mono-ubiquitination) of TRalpha, which parallels the process of TRalpha SUMOylation. Both SUMOylation and mono-ubiquitination occur at specific lysines and do not result in degradation of TRalpha. SUMOylation and mono-ubiquitination also inhibit T3-induced TRalpha activity. Interestingly, TRalpha is SUMOylated at lysines 284 and 389, both of which are within the ligand-binding domain (E/F region) of TRalpha, consistent with our findings that MuRF1 interacts with and catalyzes the addition of ubiquitin in the E/F domain of TRalpha are critical to regulation by MuRF1 (Fig. 7, lysines 187 through 389, Supplementary Fig. S3 for additional information). The physiological importance of SUMOylation in health and disease is not known; however, the common T3-mediated growth functions of TRalpha make it likely that SUMOylation in hepatocytes and pituitary parallel the critical regulation of mono-ubiquitination in cardiomyocytes reported here.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>37372</offset><text>The exaggerated hypertrophy in the MuRF1-/- hearts is consistent with an enhanced cardiomyocyte TRalpha activity (Fig. 1A, Fig. 8A). Similarly, the lack of cardiac hypertrophy in the MuRF1Tg+ hearts was consistent with in vitro findings (Fig. 1B and C, Fig. 8D). However, the baseline MuRF1Tg+ heart function worsens after 2 weeks of T3 treatment (Fig. 8C). One explanation for this may be the energetic defects seen in the MuRF1Tg+ mice, such as decreased creatine kinase activity and altered fatty acid oxidation. Conversely, the enhanced MuRF1-/- function seen with T3 stimulation (Fig. 8A) may reflect an athletic phenotype previously identified in the MuRF1-/- hearts that may be related, but not fully due to enhanced T3 activity resulting from decreased ubiquitination.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>38158</offset><text>This study may offer several clinically relevant insights into approaches to treating heart failure. TH induces molecular changes that benefit the failing heart, including the stimulation of pro-survival pathways such as Akt and mTOR that is accompanied by improved cardiac function, paralleling changes induced by exercise, mediated by IGF-1, to drive increases in contractile proteins critical to cardiac function and performance. Exercise has also been shown to increase myocardial TR expression and T3 levels in a small cohort of HF patients with ventricular assist devices, underscoring the role for TH in promoting positive adaptive remodeling of the injured heart. Exogenous approaches to supplementing TH also hold promise as low-dose T3 replacement has been shown to restore cardiac T3 levels and ameliorate dysfunction in preclinical models of heart failure. Additionally, long-term physiological T3 supplementation as an adjunct therapy in hypertensive heart disease has been beneficial in preclinical studies and may enhance ventricular remodeling in humans. The use of T3 in heart failure has been a topic of discussion for many decades, with a growing number of animal and human studies suggesting that TH treatment may contribute to improved cardiovascular outcomes, although off-target effects may limit application, particularly in patients who appear systemically euthyroid. The present studies offer insight into how one might specifically enhance the actions of TH by inhibiting MuRF1's antagonism, thereby targeting muscle-specific activation without necessarily supplementing T3 systemically.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>39775</offset><text>Supplementary Material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>39798</offset><text>           Supplementary data         </text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>39837</offset><text>This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-15-0283.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>39929</offset><text>           Declaration of interest         </text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>39973</offset><text>The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>40113</offset><text>           Author contribution         </text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>40153</offset><text>K W, J B, M P, M G, and M W conceived the concept and detailed the research design and were involved in all aspects of interpretation, discussion, writing, and editing. K W and M W performed the animal experiments. K W, W T, and M Z conceived, planned, and performed in vitro studies, then statistically analyzed and plotted, and interpreted in vitro studies. K W, J B, W T, and M W statistically analyzed, interpreted, and plotted data, wrote, and edited the manuscript.</text></passage><passage><infon key="fpage">664</infon><infon key="lpage">668</infon><infon key="name_0">surname:Adamopoulos;given-names:S</infon><infon key="name_1">surname:Gouziouta;given-names:A</infon><infon key="name_2">surname:Mantzouratou;given-names:P</infon><infon key="name_3">surname:Laoutaris;given-names:ID</infon><infon key="name_4">surname:Dritsas;given-names:A</infon><infon key="name_5">surname:Cokkinos;given-names:DV</infon><infon key="name_6">surname:Mourouzis;given-names:I</infon><infon key="name_7">surname:Sfyrakis;given-names:P</infon><infon key="name_8">surname:Iervasi;given-names:G</infon><infon key="name_9">surname:Pantos;given-names:C</infon><infon key="pub-id_doi">10.1093/icvts/ivt294</infon><infon key="pub-id_pmid">23820669</infon><infon key="section_type">REF</infon><infon key="source">Interactive CardioVascular and Thoracic Surgery</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2013</infon><offset>40625</offset><text>Thyroid hormone signalling is altered in response to physical training in patients with end-stage heart failure and mechanical assist devices: Potential physiological consequences?</text></passage><passage><infon key="fpage">1147</infon><infon key="lpage">1159</infon><infon key="name_0">surname:Arya;given-names:R</infon><infon key="name_1">surname:Kedar;given-names:V</infon><infon key="name_2">surname:Hwang;given-names:JR</infon><infon key="name_3">surname:McDonough;given-names:H</infon><infon key="name_4">surname:Li;given-names:HH</infon><infon key="name_5">surname:Taylor;given-names:J</infon><infon key="name_6">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1083/jcb.200402033</infon><infon key="pub-id_pmid">15596539</infon><infon key="section_type">REF</infon><infon key="source">Journal of Cell Biology</infon><infon key="type">ref</infon><infon key="volume">167</infon><infon key="year">2004</infon><offset>40806</offset><text>Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy</text></passage><passage><infon key="fpage">312</infon><infon key="lpage">322</infon><infon key="name_0">surname:Banerjee;given-names:R</infon><infon key="name_1">surname:He;given-names:J</infon><infon key="name_2">surname:Spaniel;given-names:C</infon><infon key="name_3">surname:Quintana;given-names:MT</infon><infon key="name_4">surname:Wang;given-names:Z</infon><infon key="name_5">surname:Bain;given-names:JR</infon><infon key="name_6">surname:Newgard;given-names:CB</infon><infon key="name_7">surname:Muehlbauer;given-names:MJ</infon><infon key="name_8">surname:Willis;given-names:MS</infon><infon key="pub-id_doi">10.1007/s11306-014-0695-1</infon><infon key="pub-id_pmid">28325996</infon><infon key="section_type">REF</infon><infon key="source">Metabolomics</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2015</infon><offset>40907</offset><text>Non-targeted metabolomics analysis of cardiac muscle ring finger-1 (MuRF1), MuRF2, and MuRF3 in vivo reveals novel and redundant metabolic changes</text></passage><passage><infon key="fpage">2946</infon><infon key="lpage">2956</infon><infon key="name_0">surname:Belakavadi;given-names:M</infon><infon key="name_1">surname:Saunders;given-names:J</infon><infon key="name_2">surname:Weisleder;given-names:N</infon><infon key="name_3">surname:Raghava;given-names:PS</infon><infon key="name_4">surname:Fondell;given-names:JD</infon><infon key="pub-id_doi">10.1210/en.2009-1241</infon><infon key="pub-id_pmid">20392835</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology</infon><infon key="type">ref</infon><infon key="volume">151</infon><infon key="year">2010</infon><offset>41054</offset><text>Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications</text></passage><passage><infon key="fpage">1822</infon><infon key="lpage">1827</infon><infon key="name_0">surname:Bengel;given-names:FM</infon><infon key="name_1">surname:Nekolla;given-names:SG</infon><infon key="name_2">surname:Ibrahim;given-names:T</infon><infon key="name_3">surname:Weniger;given-names:C</infon><infon key="name_4">surname:Ziegler;given-names:SI</infon><infon key="name_5">surname:Schwaiger;given-names:M</infon><infon key="pub-id_doi">10.1210/jcem.85.5.6520</infon><infon key="pub-id_pmid">10843159</infon><infon key="section_type">REF</infon><infon key="source">Journal of Clinical Endocrinology &amp; Metabolism</infon><infon key="type">ref</infon><infon key="volume">85</infon><infon key="year">2000</infon><offset>41208</offset><text>Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging</text></passage><passage><infon key="fpage">22804</infon><infon key="lpage">22815</infon><infon key="name_0">surname:Brooks;given-names:CL</infon><infon key="name_1">surname:Li;given-names:M</infon><infon key="name_2">surname:Gu;given-names:W</infon><infon key="pub-id_doi">10.1038/onc.2009.427</infon><infon key="pub-id_pmid">17500067</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">282</infon><infon key="year">2007</infon><offset>41377</offset><text>Mechanistic studies of MDM2-mediated ubiquitination in p53 regulation</text></passage><passage><infon key="fpage">2979</infon><infon key="lpage">2984</infon><infon key="name_0">surname:Claycomb;given-names:WC</infon><infon key="name_1">surname:Lanson;given-names:NA;suffix:Jr</infon><infon key="name_2">surname:Stallworth;given-names:BS</infon><infon key="name_3">surname:Egeland;given-names:DB</infon><infon key="name_4">surname:Delcarpio;given-names:JB</infon><infon key="name_5">surname:Bahinski;given-names:A</infon><infon key="name_6">surname:Izzo;given-names:NJ;suffix:Jr</infon><infon key="pub-id_doi">10.1073/pnas.95.6.2979</infon><infon key="pub-id_pmid">9501201</infon><infon key="section_type">REF</infon><infon key="source">PNAS</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">1998</infon><offset>41447</offset><text>HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte</text></passage><passage><infon key="fpage">8985</infon><infon key="lpage">8990</infon><infon key="name_0">surname:Dace;given-names:A</infon><infon key="name_1">surname:Zhao;given-names:L</infon><infon key="name_2">surname:Park;given-names:KS</infon><infon key="name_3">surname:Furuno;given-names:T</infon><infon key="name_4">surname:Takamura;given-names:N</infon><infon key="name_5">surname:Nakanishi;given-names:M</infon><infon key="name_6">surname:West;given-names:BL</infon><infon key="name_7">surname:Hanover;given-names:JA</infon><infon key="name_8">surname:Cheng;given-names:S</infon><infon key="pub-id_doi">10.1073/pnas.160257997</infon><infon key="pub-id_pmid">10908671</infon><infon key="section_type">REF</infon><infon key="source">PNAS</infon><infon key="type">ref</infon><infon key="volume">97</infon><infon key="year">2000</infon><offset>41567</offset><text>Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors</text></passage><passage><infon key="fpage">125</infon><infon key="lpage">132</infon><infon key="name_0">surname:Dillmann;given-names:W</infon><infon key="pub-id_doi">10.1007/s10741-008-9125-7</infon><infon key="pub-id_pmid">19125327</infon><infon key="section_type">REF</infon><infon key="source">Heart Failure Reviews</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2010</infon><offset>41658</offset><text>Cardiac hypertrophy and thyroid hormone signaling</text></passage><passage><infon key="fpage">1319</infon><infon key="lpage">1329</infon><infon key="name_0">surname:Gassanov;given-names:N</infon><infon key="name_1">surname:Er;given-names:F</infon><infon key="name_2">surname:Michels;given-names:G</infon><infon key="name_3">surname:Zagidullin;given-names:N</infon><infon key="name_4">surname:Brandt;given-names:MC</infon><infon key="name_5">surname:Hoppe;given-names:UC</infon><infon key="pub-id_doi">10.1113/jphysiol.2008.168385</infon><infon key="pub-id_pmid">19171649</infon><infon key="section_type">REF</infon><infon key="source">Journal of Physiology</infon><infon key="type">ref</infon><infon key="volume">587</infon><infon key="year">2009</infon><offset>41708</offset><text>Divergent regulation of cardiac KCND3 potassium channel expression by the thyroid hormone receptors alpha1 and beta1</text></passage><passage><infon key="fpage">H1</infon><infon key="lpage">10</infon><infon key="name_0">surname:Gerdes;given-names:AM</infon><infon key="pub-id_doi">10.1152/ajpheart.00704.2014</infon><infon key="pub-id_pmid">25380818</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Physiology: Heart and Circulatory Physiology</infon><infon key="type">ref</infon><infon key="volume">308</infon><infon key="year">2015</infon><offset>41825</offset><text>Restoration of thyroid hormone balance: A game changer in the treatment of heart failure?</text></passage><passage><infon key="fpage">385</infon><infon key="lpage">393</infon><infon key="name_0">surname:Gerdes;given-names:AM</infon><infon key="name_1">surname:Iervasi;given-names:G</infon><infon key="pub-id_doi">10.1161/CIRCULATIONAHA.109.917922</infon><infon key="pub-id_pmid">20660814</infon><infon key="section_type">REF</infon><infon key="source">Circulation</infon><infon key="type">ref</infon><infon key="volume">122</infon><infon key="year">2010</infon><offset>41915</offset><text>Thyroid replacement therapy and heart failure</text></passage><passage><infon key="fpage">269</infon><infon key="lpage">279</infon><infon key="name_0">surname:Ghose Roy;given-names:S</infon><infon key="name_1">surname:Mishra;given-names:S</infon><infon key="name_2">surname:Ghosh;given-names:G</infon><infon key="name_3">surname:Bandyopadhyay;given-names:A</infon><infon key="pub-id_doi">10.1016/j.matbio.2006.12.005</infon><infon key="pub-id_pmid">17275272</infon><infon key="section_type">REF</infon><infon key="source">Matrix Biology</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2007</infon><offset>41961</offset><text>Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1</text></passage><passage><infon key="fpage">97</infon><infon key="name_0">surname:He;given-names:J</infon><infon key="name_1">surname:Quintana;given-names:MT</infon><infon key="name_2">surname:Sullivan;given-names:J</infon><infon key="name_3">surname:TLP</infon><infon key="name_4">surname:TJG</infon><infon key="name_5">surname:Schisler</infon><infon key="name_6">surname:Hill;given-names:JC</infon><infon key="name_7">surname:Yates;given-names:JA</infon><infon key="name_8">surname:Mapanga;given-names:CC</infon><infon key="name_9">surname:Essop;given-names:RFMF</infon><infon key="pub-id_doi">10.1186/s12933-015-0252-x</infon><infon key="pub-id_pmid">26242235</infon><infon key="section_type">REF</infon><infon key="source">Cardiovascular Diabetology</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2015</infon><offset>42056</offset><text>MuRF2 regulates PPARgamma1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet</text></passage><passage><infon key="fpage">106</infon><infon key="lpage">110</infon><infon key="name_0">surname:Hirotani;given-names:M</infon><infon key="name_1">surname:Tsukamoto;given-names:T</infon><infon key="name_2">surname:Bourdeaux;given-names:J</infon><infon key="name_3">surname:Sadano;given-names:H</infon><infon key="name_4">surname:Osumi;given-names:T</infon><infon key="pub-id_doi">10.1006/bbrc.2001.5739</infon><infon key="pub-id_pmid">11594759</infon><infon key="section_type">REF</infon><infon key="source">Biochemical and Biophysical Research Communications</infon><infon key="type">ref</infon><infon key="volume">288</infon><infon key="year">2001</infon><offset>42186</offset><text>Stabilization of peroxisome proliferator-activated receptor alpha by the ligand</text></passage><passage><infon key="fpage">14396</infon><infon key="lpage">14402</infon><infon key="name_0">surname:Hoeck;given-names:W</infon><infon key="name_1">surname:Rusconi;given-names:S</infon><infon key="name_2">surname:Groner;given-names:B</infon><infon key="pub-id_pmid">2668288</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">264</infon><infon key="year">1989</infon><offset>42266</offset><text>Down-regulation and phosphorylation of glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum against a bacterially expressed receptor fragment</text></passage><passage><infon key="fpage">92</infon><infon key="lpage">101</infon><infon key="name_0">surname:Hwee;given-names:DT</infon><infon key="name_1">surname:Baehr;given-names:LM</infon><infon key="name_2">surname:Philp;given-names:A</infon><infon key="name_3">surname:Baar;given-names:K</infon><infon key="name_4">surname:Bodine;given-names:SC</infon><infon key="pub-id_doi">10.1111/acel.2014.13.issue-1</infon><infon key="pub-id_pmid">23941502</infon><infon key="section_type">REF</infon><infon key="source">Aging Cell</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2014</infon><offset>42444</offset><text>Maintenance of muscle mass and load-induced growth in muscle RINGfinger 1 null mice with age</text></passage><passage><infon key="fpage">S71</infon><infon key="issue">Supplement 11</infon><infon key="lpage">74</infon><infon key="name_0">surname:Iervasi;given-names:G</infon><infon key="name_1">surname:Nicolini;given-names:G</infon><infon key="pub-id_doi">10.1007/s11739-013-0911-4</infon><infon key="pub-id_pmid">23435988</infon><infon key="section_type">REF</infon><infon key="source">Internal and Emergency Medicine</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2013</infon><offset>42537</offset><text>Thyroid hormone and cardiovascular system: From basic concepts to clinical application</text></passage><passage><infon key="fpage">483</infon><infon key="lpage">490</infon><infon key="name_0">surname:Ismail;given-names:A</infon><infon key="name_1">surname:Nawaz;given-names:Z</infon><infon key="pub-id_doi">10.4103/1735-1995.172796</infon><infon key="pub-id_pmid">16081369</infon><infon key="section_type">REF</infon><infon key="source">International Union of Biochemistry and Molecular Biology Life</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2005</infon><offset>42624</offset><text>Nuclear hormone receptor degradation and gene transcription: An update</text></passage><passage><infon key="fpage">3997</infon><infon key="lpage">4006</infon><infon key="name_0">surname:Jung;given-names:YS</infon><infon key="name_1">surname:Hakem;given-names:A</infon><infon key="name_2">surname:Hakem;given-names:R</infon><infon key="name_3">surname:Chen;given-names:X</infon><infon key="pub-id_doi">10.1371/journal.pgen.1002360</infon><infon key="pub-id_pmid">21791603</infon><infon key="section_type">REF</infon><infon key="source">Molecular and Cellular Biology</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2011</infon><offset>42695</offset><text>Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis</text></passage><passage><infon key="fpage">18135</infon><infon key="lpage">18140</infon><infon key="name_0">surname:Kedar;given-names:V</infon><infon key="name_1">surname:McDonough;given-names:H</infon><infon key="name_2">surname:Arya;given-names:R</infon><infon key="name_3">surname:Li;given-names:HH</infon><infon key="name_4">surname:Rockman;given-names:HA</infon><infon key="name_5">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1073/pnas.0404341102</infon><infon key="pub-id_pmid">15601779</infon><infon key="section_type">REF</infon><infon key="source">PNAS</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2004</infon><offset>42796</offset><text>Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I</text></passage><passage><infon key="fpage">H813</infon><infon key="lpage">821</infon><infon key="name_0">surname:Kenessey;given-names:A</infon><infon key="name_1">surname:Ojamaa;given-names:K</infon><infon key="pub-id_doi">10.1152/ajpheart.00595.2012</infon><infon key="pub-id_pmid">15498821</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Physiology: Heart and Circulatory Physiology</infon><infon key="type">ref</infon><infon key="volume">288</infon><infon key="year">2005</infon><offset>42891</offset><text>Ligand-mediated decrease of thyroid hormone receptor-alpha1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability</text></passage><passage><infon key="fpage">17375</infon><infon key="lpage">17386</infon><infon key="name_0">surname:Kim;given-names:HT</infon><infon key="name_1">surname:Kim;given-names:KP</infon><infon key="name_2">surname:Lledias;given-names:F</infon><infon key="name_3">surname:Kisselev;given-names:AF</infon><infon key="name_4">surname:Scaglione;given-names:KM</infon><infon key="name_5">surname:Skowyra;given-names:D</infon><infon key="name_6">surname:Gygi;given-names:SP</infon><infon key="name_7">surname:Goldberg;given-names:AL</infon><infon key="pub-id_doi">10.1074/jbc.M609659200</infon><infon key="pub-id_pmid">17426036</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">282</infon><infon key="year">2007</infon><offset>43032</offset><text>Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages</text></passage><passage><infon key="fpage">33280</infon><infon key="lpage">33288</infon><infon key="name_0">surname:Kopf;given-names:E</infon><infon key="name_1">surname:Plassat;given-names:JL</infon><infon key="name_2">surname:Vivat;given-names:V</infon><infon key="name_3">surname:de The;given-names:H</infon><infon key="name_4">surname:Chambon;given-names:P</infon><infon key="name_5">surname:Rochette-Egly;given-names:C</infon><infon key="pub-id_doi">10.1074/jbc.M002840200</infon><infon key="pub-id_pmid">10869350</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">275</infon><infon key="year">2000</infon><offset>43214</offset><text>Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway</text></passage><passage><infon key="fpage">31357</infon><infon key="lpage">31367</infon><infon key="name_0">surname:Lai;given-names:Z</infon><infon key="name_1">surname:Ferry;given-names:KV</infon><infon key="name_2">surname:Diamond;given-names:MA</infon><infon key="name_3">surname:Wee;given-names:KE</infon><infon key="name_4">surname:Kim;given-names:YB</infon><infon key="name_5">surname:Ma;given-names:J</infon><infon key="name_6">surname:Yang;given-names:T</infon><infon key="name_7">surname:Benfield;given-names:PA</infon><infon key="name_8">surname:Copeland;given-names:RA</infon><infon key="name_9">surname:Auger;given-names:KR</infon><infon key="pub-id_doi">10.1074/jbc.M011517200</infon><infon key="pub-id_pmid">11397792</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">276</infon><infon key="year">2001</infon><offset>43404</offset><text>Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization</text></passage><passage><infon key="fpage">1032</infon><infon key="lpage">1037</infon><infon key="name_0">surname:Lange;given-names:CA</infon><infon key="name_1">surname:Shen;given-names:T</infon><infon key="name_2">surname:Horwitz;given-names:KB</infon><infon key="pub-id_doi">10.1128/MCB.21.18.6122-6131.2001</infon><infon key="pub-id_pmid">10655479</infon><infon key="section_type">REF</infon><infon key="source">PNAS</infon><infon key="type">ref</infon><infon key="volume">97</infon><infon key="year">2000</infon><offset>43506</offset><text>Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26 S proteasome</text></passage><passage><infon key="fpage">86</infon><infon key="lpage">92</infon><infon key="name_0">surname:Lee;given-names:JT</infon><infon key="name_1">surname:Gu;given-names:W</infon><infon key="pub-id_doi">10.1038/cdd.2009.77</infon><infon key="pub-id_pmid">19543236</infon><infon key="section_type">REF</infon><infon key="source">Cell Death And Differentiation</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2010</infon><offset>43653</offset><text>The multiple levels of regulation by p53 ubiquitination</text></passage><passage><infon key="fpage">30</infon><infon key="name_0">surname:Lelievre;given-names:H</infon><infon key="name_1">surname:Chevrier;given-names:V</infon><infon key="name_2">surname:Tassin;given-names:AM</infon><infon key="name_3">surname:Birnbaum;given-names:D</infon><infon key="pub-id_doi">10.1186/1476-4598-7-30</infon><infon key="pub-id_pmid">18412956</infon><infon key="section_type">REF</infon><infon key="source">Molecular Cancer</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2008</infon><offset>43709</offset><text>Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome</text></passage><passage><infon key="fpage">1043</infon><infon key="lpage">1058</infon><infon key="name_0">surname:Li;given-names:HH</infon><infon key="name_1">surname:Du;given-names:J</infon><infon key="name_2">surname:Fan;given-names:YN</infon><infon key="name_3">surname:Zhang;given-names:ML</infon><infon key="name_4">surname:Liu;given-names:DP</infon><infon key="name_5">surname:Li;given-names:L</infon><infon key="name_6">surname:Lockyer;given-names:P</infon><infon key="name_7">surname:Kang;given-names:EY</infon><infon key="name_8">surname:Patterson;given-names:C</infon><infon key="name_9">surname:Willis;given-names:MS</infon><infon key="pub-id_doi">10.1016/j.ajpath.2010.11.049</infon><infon key="pub-id_pmid">21356357</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Pathology</infon><infon key="type">ref</infon><infon key="volume">178</infon><infon key="year">2011</infon><offset>43839</offset><text>The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho-c-Jun</text></passage><passage><infon key="fpage">1058</infon><infon key="lpage">1071</infon><infon key="name_0">surname:Li;given-names:HH</infon><infon key="name_1">surname:Kedar;given-names:V</infon><infon key="name_2">surname:Zhang;given-names:C</infon><infon key="name_3">surname:McDonough;given-names:H</infon><infon key="name_4">surname:Arya;given-names:R</infon><infon key="name_5">surname:Wang;given-names:DZ</infon><infon key="name_6">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1172/JCI200422220</infon><infon key="pub-id_pmid">15489953</infon><infon key="section_type">REF</infon><infon key="source">Journal of Clinical Investigation</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">2004</infon><offset>43976</offset><text>Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex</text></passage><passage><infon key="fpage">1686</infon><infon key="lpage">1694</infon><infon key="name_0">surname:Li;given-names:XY</infon><infon key="name_1">surname:Boudjelal;given-names:M</infon><infon key="name_2">surname:Xiao;given-names:JH</infon><infon key="name_3">surname:Peng;given-names:ZH</infon><infon key="name_4">surname:Asuru;given-names:A</infon><infon key="name_5">surname:Kang;given-names:S</infon><infon key="name_6">surname:Fisher;given-names:GJ</infon><infon key="name_7">surname:Voorhees;given-names:JJ</infon><infon key="pub-id_doi">10.1210/mend.13.10.0362</infon><infon key="pub-id_pmid">10517670</infon><infon key="section_type">REF</infon><infon key="source">Molecular Endocrinology</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1999</infon><offset>44110</offset><text>1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin</text></passage><passage><infon key="fpage">36570</infon><infon key="lpage">36576</infon><infon key="name_0">surname:Lin;given-names:HK</infon><infon key="name_1">surname:Altuwaijri;given-names:S</infon><infon key="name_2">surname:Lin;given-names:WJ</infon><infon key="name_3">surname:Kan;given-names:PY</infon><infon key="name_4">surname:Collins;given-names:LL</infon><infon key="name_5">surname:Chang;given-names:C</infon><infon key="pub-id_doi">10.1074/jbc.M204751200</infon><infon key="pub-id_pmid">12119296</infon><infon key="section_type">REF</infon><infon key="source">The Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">277</infon><infon key="year">2002</infon><offset>44242</offset><text>Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells</text></passage><passage><infon key="fpage">572</infon><infon key="lpage">577</infon><infon key="name_0">surname:Lisby;given-names:M</infon><infon key="name_1">surname:Mortensen;given-names:UH</infon><infon key="name_2">surname:Rothstein;given-names:R</infon><infon key="pub-id_doi">10.1016/j.dnarep.2009.10.001</infon><infon key="pub-id_pmid">12766777</infon><infon key="section_type">REF</infon><infon key="source">Nature Cell Biology</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2003</infon><offset>44438</offset><text>Colocalization of multiple DNA double-strand breaks at a single Rad52 repair centre</text></passage><passage><infon key="fpage">36499</infon><infon key="lpage">36508</infon><infon key="name_0">surname:Liu;given-names:YY</infon><infon key="name_1">surname:Kogai;given-names:T</infon><infon key="name_2">surname:Schultz;given-names:JJ</infon><infon key="name_3">surname:Mody;given-names:K</infon><infon key="name_4">surname:Brent;given-names:GA</infon><infon key="pub-id_doi">10.1074/jbc.M112.344317</infon><infon key="pub-id_pmid">22930759</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">287</infon><infon key="year">2012</infon><offset>44522</offset><text>Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation</text></passage><passage><infon key="fpage">76</infon><infon key="lpage">90</infon><infon key="name_0">surname:Ma;given-names:Y</infon><infon key="name_1">surname:Fan;given-names:S</infon><infon key="name_2">surname:Hu;given-names:C</infon><infon key="name_3">surname:Meng;given-names:Q</infon><infon key="name_4">surname:Fuqua;given-names:SA</infon><infon key="name_5">surname:Pestell;given-names:RG</infon><infon key="name_6">surname:Tomita;given-names:YA</infon><infon key="name_7">surname:Rosen;given-names:EM</infon><infon key="pub-id_doi">10.1210/me.2009-0218</infon><infon key="pub-id_pmid">19887647</infon><infon key="section_type">REF</infon><infon key="source">Molecular Endocrinology</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2010</infon><offset>44669</offset><text>BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha</text></passage><passage><infon key="fpage">133</infon><infon key="lpage">142</infon><infon key="name_0">surname:Mansen;given-names:A</infon><infon key="name_1">surname:Tiselius;given-names:C</infon><infon key="name_2">surname:Sand;given-names:P</infon><infon key="name_3">surname:Fauconnier;given-names:J</infon><infon key="name_4">surname:Westerblad;given-names:H</infon><infon key="name_5">surname:Rydqvist;given-names:B</infon><infon key="name_6">surname:Vennstrom;given-names:B</infon><infon key="pub-id_doi">10.1111/aps.2010.198.issue-2</infon><infon key="section_type">REF</infon><infon key="source">Acta physiologica (Oxford, England)</infon><infon key="type">ref</infon><infon key="volume">198</infon><infon key="year">2010</infon><offset>44743</offset><text>Thyroid hormone receptor alpha can control action potential duration in mouse ventricular myocytes through the KCNE1 ion channel subunit</text></passage><passage><infon key="fpage">958626</infon><infon key="name_0">surname:Mourouzis;given-names:I</infon><infon key="name_1">surname:Forini;given-names:F</infon><infon key="name_2">surname:Pantos;given-names:C</infon><infon key="name_3">surname:Iervasi;given-names:G</infon><infon key="pub-id_doi">10.4061/2011/958626</infon><infon key="pub-id_pmid">21765997</infon><infon key="section_type">REF</infon><infon key="source">Journal of Thyroid Research</infon><infon key="type">ref</infon><infon key="volume">2011</infon><infon key="year">2011</infon><offset>44880</offset><text>Thyroid hormone and cardiac disease: From basic concepts to clinical application</text></passage><passage><infon key="fpage">1387</infon><infon key="lpage">1393</infon><infon key="name_0">surname:Mourouzis;given-names:I</infon><infon key="name_1">surname:Giagourta;given-names:I</infon><infon key="name_2">surname:Galanopoulos;given-names:G</infon><infon key="name_3">surname:Mantzouratou;given-names:P</infon><infon key="name_4">surname:Kostakou;given-names:E</infon><infon key="name_5">surname:Kokkinos;given-names:AD</infon><infon key="name_6">surname:Tentolouris;given-names:N</infon><infon key="name_7">surname:Pantos;given-names:C</infon><infon key="pub-id_doi">10.1016/j.metabol.2013.05.008</infon><infon key="pub-id_pmid">23773982</infon><infon key="section_type">REF</infon><infon key="source">Metabolism</infon><infon key="type">ref</infon><infon key="volume">62</infon><infon key="year">2013a</infon><offset>44961</offset><text>Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: A response associated with up-regulation of Akt/mTOR and AMPK activation</text></passage><passage><infon key="fpage">97</infon><infon key="lpage">105</infon><infon key="name_0">surname:Mourouzis;given-names:I</infon><infon key="name_1">surname:Kostakou;given-names:E</infon><infon key="name_2">surname:Galanopoulos;given-names:G</infon><infon key="name_3">surname:Mantzouratou;given-names:P</infon><infon key="name_4">surname:Pantos;given-names:C</infon><infon key="pub-id_doi">10.1177/1074248414524481</infon><infon key="pub-id_pmid">23532677</infon><infon key="section_type">REF</infon><infon key="source">Molecular and Cellular Biochemistry</infon><infon key="type">ref</infon><infon key="volume">379</infon><infon key="year">2013b</infon><offset>45129</offset><text>Inhibition of thyroid hormone receptor alpha1 impairs post-ischemic cardiac performance after myocardial infarction in mice</text></passage><passage><infon key="fpage">235</infon><infon key="lpage">243</infon><infon key="name_0">surname:Mourouzis;given-names:I</infon><infon key="name_1">surname:Mantzouratou;given-names:P</infon><infon key="name_2">surname:Galanopoulos;given-names:G</infon><infon key="name_3">surname:Kostakou;given-names:E</infon><infon key="name_4">surname:Roukounakis;given-names:N</infon><infon key="name_5">surname:Kokkinos;given-names:AD</infon><infon key="name_6">surname:Cokkinos;given-names:DV</infon><infon key="name_7">surname:Pantos;given-names:C</infon><infon key="pub-id_doi">10.1007/s11010-011-1175-9</infon><infon key="pub-id_pmid">22134702</infon><infon key="section_type">REF</infon><infon key="source">Molecular and Cellular Biochemistry</infon><infon key="type">ref</infon><infon key="volume">363</infon><infon key="year">2012</infon><offset>45253</offset><text>Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: Potential involvement of Akt and ERK signalings</text></passage><passage><infon key="fpage">1858</infon><infon key="lpage">1862</infon><infon key="name_0">surname:Nawaz;given-names:Z</infon><infon key="name_1">surname:Lonard;given-names:DM</infon><infon key="name_2">surname:Dennis;given-names:AP</infon><infon key="name_3">surname:Smith;given-names:CL</infon><infon key="name_4">surname:O'Malley;given-names:BW</infon><infon key="pub-id_doi">10.1073/pnas.96.5.1858</infon><infon key="pub-id_pmid">10051559</infon><infon key="section_type">REF</infon><infon key="source">PNAS</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">1999</infon><offset>45381</offset><text>Proteasome-dependent degradation of the human estrogen receptor</text></passage><passage><infon key="fpage">113</infon><infon key="lpage">119</infon><infon key="name_0">surname:Ojamaa;given-names:K</infon><infon key="pub-id_doi">10.1016/j.vph.2009.11.008</infon><infon key="pub-id_pmid">20005976</infon><infon key="section_type">REF</infon><infon key="source">Vascular Pharmacology</infon><infon key="type">ref</infon><infon key="volume">52</infon><infon key="year">2010</infon><offset>45445</offset><text>Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy</text></passage><passage><infon key="fpage">718</infon><infon key="lpage">724</infon><infon key="name_0">surname:Pantos;given-names:C</infon><infon key="name_1">surname:Mourouzis;given-names:I</infon><infon key="name_2">surname:Galanopoulos;given-names:G</infon><infon key="name_3">surname:Gavra;given-names:M</infon><infon key="name_4">surname:Perimenis;given-names:P</infon><infon key="name_5">surname:Spanou;given-names:D</infon><infon key="name_6">surname:Cokkinos;given-names:DV</infon><infon key="pub-id_doi">10.1055/s-0030-1255035</infon><infon key="pub-id_pmid">20560106</infon><infon key="section_type">REF</infon><infon key="source">Hormone And Metabolic Research</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2010</infon><offset>45513</offset><text>Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: The potential role of tissue hypothyroidism</text></passage><passage><infon key="fpage">333</infon><infon key="lpage">339</infon><infon key="name_0">surname:Pantos;given-names:C</infon><infon key="name_1">surname:Mourouzis;given-names:I</infon><infon key="name_2">surname:Markakis;given-names:K</infon><infon key="name_3">surname:Dimopoulos;given-names:A</infon><infon key="name_4">surname:Xinaris;given-names:C</infon><infon key="name_5">surname:Kokkinos;given-names:AD</infon><infon key="name_6">surname:Panagiotou;given-names:M</infon><infon key="name_7">surname:Cokkinos;given-names:DV</infon><infon key="pub-id_doi">10.1016/j.ejcts.2007.05.004</infon><infon key="section_type">REF</infon><infon key="source">European Journal Cardio-Thoracic Surgery</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2007a</infon><offset>45647</offset><text>Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats</text></passage><passage><infon key="fpage">235</infon><infon key="lpage">241</infon><infon key="name_0">surname:Pantos;given-names:C</infon><infon key="name_1">surname:Mourouzis;given-names:I</infon><infon key="name_2">surname:Saranteas;given-names:T</infon><infon key="name_3">surname:Brozou;given-names:V</infon><infon key="name_4">surname:Galanopoulos;given-names:G</infon><infon key="name_5">surname:Kostopanagiotou;given-names:G</infon><infon key="name_6">surname:Cokkinos;given-names:DV</infon><infon key="pub-id_doi">10.1007/s11010-011-0791-8</infon><infon key="pub-id_pmid">21442236</infon><infon key="section_type">REF</infon><infon key="source">Molecular and Cellular Biochemistry</infon><infon key="type">ref</infon><infon key="volume">353</infon><infon key="year">2011</infon><offset>45767</offset><text>Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRalpha1 receptor</text></passage><passage><infon key="fpage">65</infon><infon key="lpage">72</infon><infon key="name_0">surname:Pantos;given-names:C</infon><infon key="name_1">surname:Xinaris;given-names:C</infon><infon key="name_2">surname:Mourouzis;given-names:I</infon><infon key="name_3">surname:Malliopoulou;given-names:V</infon><infon key="name_4">surname:Kardami;given-names:E</infon><infon key="name_5">surname:Cokkinos;given-names:DV</infon><infon key="pub-id_doi">10.1007/s11010-006-9323-3</infon><infon key="pub-id_pmid">17024559</infon><infon key="section_type">REF</infon><infon key="source">Molecular and Cellular Biochemistry</infon><infon key="type">ref</infon><infon key="volume">297</infon><infon key="year">2007b</infon><offset>45863</offset><text>Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: Potential therapeutic implications in reversing cardiac remodeling?</text></passage><passage><infon key="fpage">253</infon><infon key="lpage">269</infon><infon key="name_0">surname:Pantos;given-names:C</infon><infon key="name_1">surname:Xinaris;given-names:C</infon><infon key="name_2">surname:Mourouzis;given-names:I</infon><infon key="name_3">surname:Perimenis;given-names:P</infon><infon key="name_4">surname:Politi;given-names:E</infon><infon key="name_5">surname:Spanou;given-names:D</infon><infon key="name_6">surname:Cokkinos;given-names:DV</infon><infon key="section_type">REF</infon><infon key="source">Journal of Physiology and Pharmacology</infon><infon key="type">ref</infon><infon key="volume">59</infon><infon key="year">2008</infon><offset>46015</offset><text>Thyroid hormone receptor alpha 1: A switch to cardiac cell metamorphosis?</text></passage><passage><infon key="fpage">175</infon><infon key="lpage">186</infon><infon key="name_0">surname:Patel;given-names:H</infon><infon key="name_1">surname:Truant;given-names:R</infon><infon key="name_2">surname:Rachubinski;given-names:RA</infon><infon key="name_3">surname:Capone;given-names:JP</infon><infon key="pub-id_doi">10.1242/jcs.01600</infon><infon key="pub-id_pmid">15615782</infon><infon key="section_type">REF</infon><infon key="source">Journal of Cell Science</infon><infon key="type">ref</infon><infon key="volume">118</infon><infon key="year">2005</infon><offset>46089</offset><text>Activity and subcellular compartmentalization of peroxisome proliferator-activated receptor alpha are altered by the centrosome-associated protein CAP350</text></passage><passage><infon key="fpage">265</infon><infon key="lpage">273</infon><infon key="name_0">surname:Periasamy;given-names:M</infon><infon key="name_1">surname:Bhupathy;given-names:P</infon><infon key="name_2">surname:Babu;given-names:GJ</infon><infon key="pub-id_doi">10.1016/j.yjmcc.2009.07.014</infon><infon key="pub-id_pmid">18006443</infon><infon key="section_type">REF</infon><infon key="source">Cardiovascular Research</infon><infon key="type">ref</infon><infon key="volume">77</infon><infon key="year">2008</infon><offset>46243</offset><text>Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology</text></passage><passage><infon key="fpage">36</infon><infon key="name_0">surname:Quintana;given-names:MT</infon><infon key="name_1">surname:He;given-names:J</infon><infon key="name_2">surname:Sullivan;given-names:J</infon><infon key="name_3">surname:Grevengoed;given-names:T</infon><infon key="name_4">surname:Schisler;given-names:J</infon><infon key="name_5">surname:Han;given-names:Y</infon><infon key="name_6">surname:Hill;given-names:JA</infon><infon key="name_7">surname:Yates;given-names:CC</infon><infon key="name_8">surname:Stansfield;given-names:WE</infon><infon key="name_9">surname:Mapanga;given-names:RF</infon><infon key="pub-id_doi">10.1186/s12902-015-0028-z</infon><infon key="pub-id_pmid">26215257</infon><infon key="section_type">REF</infon><infon key="source">BMC Endocrine Disorders</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2015</infon><offset>46369</offset><text>Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet</text></passage><passage><infon key="fpage">141</infon><infon key="lpage">149</infon><infon key="name_0">surname:Rajagopalan;given-names:V</infon><infon key="name_1">surname:Gerdes;given-names:AM</infon><infon key="pub-id_doi">10.1007/s11897-014-0246-0</infon><infon key="pub-id_pmid">25492377</infon><infon key="section_type">REF</infon><infon key="source">Current Heart Failure Reports</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2015</infon><offset>46458</offset><text>Role of thyroid hormones in ventricular remodeling</text></passage><passage><infon key="fpage">36</infon><infon key="lpage">48</infon><infon key="name_0">surname:Rodriguez;given-names:JE</infon><infon key="name_1">surname:Liao;given-names:JY</infon><infon key="name_2">surname:He;given-names:J</infon><infon key="name_3">surname:Schisler;given-names:JC</infon><infon key="name_4">surname:Newgard;given-names:CB</infon><infon key="name_5">surname:Drujan;given-names:D</infon><infon key="name_6">surname:Glass;given-names:DJ</infon><infon key="name_7">surname:Frederick;given-names:CB</infon><infon key="name_8">surname:Yoder;given-names:BC</infon><infon key="name_9">surname:Lalush;given-names:DS</infon><infon key="pub-id_doi">10.1016/j.mce.2015.06.008</infon><infon key="pub-id_pmid">26116825</infon><infon key="section_type">REF</infon><infon key="source">Molecular and Cellular Endocrinology</infon><infon key="type">ref</infon><infon key="volume">413</infon><infon key="year">2015</infon><offset>46509</offset><text>The ubiquitin ligase MuRF1 regulates PPARalpha activity in the heart by enhancing nuclear export via monoubiquitination</text></passage><passage><infon key="fpage">457</infon><infon key="lpage">462</infon><infon key="name_0">surname:Sabatino;given-names:L</infon><infon key="name_1">surname:Gliozheni;given-names:E</infon><infon key="name_2">surname:Molinaro;given-names:S</infon><infon key="name_3">surname:Bonotti;given-names:A</infon><infon key="name_4">surname:Azzolina;given-names:S</infon><infon key="name_5">surname:Popoff;given-names:G</infon><infon key="name_6">surname:Carpi;given-names:A</infon><infon key="name_7">surname:Iervasi;given-names:G</infon><infon key="pub-id_doi">10.1016/j.biopha.2007.04.002</infon><infon key="pub-id_pmid">17560756</infon><infon key="section_type">REF</infon><infon key="source">Biomedicine &amp; Pharmacotherapy</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2007</infon><offset>46629</offset><text>Thyroid hormone receptor and IGF1/IGFR systems: Possible relations in the human heart</text></passage><passage><infon key="fpage">739</infon><infon key="lpage">749</infon><infon key="name_0">surname:Vandenbroucke St Amant;given-names:E</infon><infon key="name_1">surname:Tauseef;given-names:M</infon><infon key="name_2">surname:Vogel;given-names:SM</infon><infon key="name_3">surname:Gao;given-names:XP</infon><infon key="name_4">surname:Mehta;given-names:D</infon><infon key="name_5">surname:Komarova;given-names:YA</infon><infon key="name_6">surname:Malik;given-names:AB</infon><infon key="pub-id_doi">10.1161/CIRCRESAHA.112.269654</infon><infon key="pub-id_pmid">22798526</infon><infon key="section_type">REF</infon><infon key="source">Circulation Research</infon><infon key="type">ref</infon><infon key="volume">111</infon><infon key="year">2012</infon><offset>46715</offset><text>PKCalpha activation of p120-catenin serine 879 phospho-switch disassembles VE-cadherin junctions and disrupts vascular integrity</text></passage><passage><infon key="fpage">E732</infon><infon key="lpage">E739</infon><infon key="name_0">surname:Wadosky;given-names:KM</infon><infon key="name_1">surname:Rodriguez;given-names:JE</infon><infon key="name_2">surname:Hite;given-names:RL</infon><infon key="name_3">surname:Min;given-names:JN</infon><infon key="name_4">surname:Walton;given-names:B</infon><infon key="name_5">surname:Willis;given-names:MS</infon><infon key="pub-id_doi">10.1152/ajpendo.00326.2013</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Physiology - Endocrinology and Metabolism</infon><infon key="type">ref</infon><infon key="volume">306</infon><infon key="year">2014</infon><offset>46844</offset><text>Muscle RING Finger-1 Attenuates IGF-1-dependent cardiomyocyte hypertrophy by inhibiting JNK signaling</text></passage><passage><infon key="fpage">302</infon><infon key="lpage">312</infon><infon key="name_0">surname:Weltman;given-names:NY</infon><infon key="name_1">surname:Ojamaa;given-names:K</infon><infon key="name_2">surname:Schlenker;given-names:EH</infon><infon key="name_3">surname:Chen;given-names:YF</infon><infon key="name_4">surname:Zucchi;given-names:R</infon><infon key="name_5">surname:Saba;given-names:A</infon><infon key="name_6">surname:Colligiani;given-names:D</infon><infon key="name_7">surname:Rajagopalan;given-names:V</infon><infon key="name_8">surname:Pol;given-names:CJ</infon><infon key="name_9">surname:Gerdes;given-names:AM</infon><infon key="pub-id_doi">10.2119/molmed.2013.00040</infon><infon key="pub-id_pmid">24960246</infon><infon key="section_type">REF</infon><infon key="source">Molecular Medicine</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2014</infon><offset>46946</offset><text>Low-dose T(3) replacement restores depressed cardiac T(3) levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus</text></passage><passage><infon key="fpage">H823</infon><infon key="lpage">829</infon><infon key="name_0">surname:White;given-names:SM</infon><infon key="name_1">surname:Constantin;given-names:PE</infon><infon key="name_2">surname:Claycomb;given-names:WC</infon><infon key="pub-id_doi">10.1152/ajpheart.00986.2003</infon><infon key="pub-id_pmid">14766671</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Physiology: Heart and Circulatory Physiology</infon><infon key="type">ref</infon><infon key="volume">286</infon><infon key="year">2004</infon><offset>47117</offset><text>Cardiac physiology at the cellular level: Use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function</text></passage><passage><infon key="fpage">456</infon><infon key="lpage">459</infon><infon key="name_0">surname:Willis;given-names:MS</infon><infon key="name_1">surname:Ike;given-names:C</infon><infon key="name_2">surname:Li;given-names:L</infon><infon key="name_3">surname:Wang;given-names:DZ</infon><infon key="name_4">surname:Glass;given-names:DJ</infon><infon key="name_5">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1161/01.RES.0000259559.48597.32</infon><infon key="pub-id_pmid">17272810</infon><infon key="section_type">REF</infon><infon key="source">Circulation Research</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="year">2007</infon><offset>47253</offset><text>Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo</text></passage><passage><infon key="fpage">H997</infon><infon key="lpage">H1006</infon><infon key="name_0">surname:Willis;given-names:MS</infon><infon key="name_1">surname:Rojas;given-names:M</infon><infon key="name_2">surname:Li;given-names:L</infon><infon key="name_3">surname:Selzman;given-names:CH</infon><infon key="name_4">surname:Tang;given-names:RH</infon><infon key="name_5">surname:Stansfield;given-names:WE</infon><infon key="name_6">surname:Rodriguez;given-names:JE</infon><infon key="name_7">surname:Glass;given-names:DJ</infon><infon key="name_8">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1152/ajpheart.00660.2008</infon><infon key="pub-id_pmid">19168726</infon><infon key="section_type">REF</infon><infon key="source">American Journal of Physiology: Heart and Circulatory Physiology</infon><infon key="type">ref</infon><infon key="volume">296</infon><infon key="year">2009a</infon><offset>47343</offset><text>Muscle ring finger 1 mediates cardiac atrophy in vivo</text></passage><passage><infon key="fpage">80</infon><infon key="lpage">88</infon><infon key="name_0">surname:Willis;given-names:MS</infon><infon key="name_1">surname:Schisler;given-names:JC</infon><infon key="name_2">surname:Li;given-names:L</infon><infon key="name_3">surname:Rodriguez;given-names:JE</infon><infon key="name_4">surname:Hilliard;given-names:EG</infon><infon key="name_5">surname:Charles;given-names:PC</infon><infon key="name_6">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1161/CIRCRESAHA.109.194928</infon><infon key="pub-id_pmid">19498199</infon><infon key="section_type">REF</infon><infon key="source">Circulation Research</infon><infon key="type">ref</infon><infon key="volume">105</infon><infon key="year">2009b</infon><offset>47397</offset><text>Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo</text></passage><passage><infon key="fpage">39</infon><infon key="lpage">50</infon><infon key="name_0">surname:Willis;given-names:MS</infon><infon key="name_1">surname:Wadosky;given-names:KM</infon><infon key="name_2">surname:Rodriguez;given-names:JE</infon><infon key="name_3">surname:Schisler;given-names:JC</infon><infon key="name_4">surname:Lockyer;given-names:P</infon><infon key="name_5">surname:Hilliard;given-names:EG</infon><infon key="name_6">surname:Glass;given-names:DJ</infon><infon key="name_7">surname:Patterson;given-names:C</infon><infon key="pub-id_doi">10.1002/cbf.v32.1</infon><infon key="pub-id_pmid">23512667</infon><infon key="section_type">REF</infon><infon key="source">Cell Biochemistry and Function</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2014</infon><offset>47476</offset><text>Muscle ring finger 1 and muscle ring finger 2 are necessary but functionally redundant during developmental cardiac growth and regulate E2F1-mediated gene expression in vivo</text></passage><passage><infon key="fpage">713</infon><infon key="lpage">722</infon><infon key="name_0">surname:Witt;given-names:SH</infon><infon key="name_1">surname:Granzier;given-names:H</infon><infon key="name_2">surname:Witt;given-names:CC</infon><infon key="name_3">surname:Labeit;given-names:S</infon><infon key="pub-id_doi">10.1016/j.jmb.2005.05.021</infon><infon key="pub-id_pmid">15967462</infon><infon key="section_type">REF</infon><infon key="source">Journal of Molecular Biology</infon><infon key="type">ref</infon><infon key="volume">350</infon><infon key="year">2005</infon><offset>47650</offset><text>MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: Towards understanding MURF-dependent muscle ubiquitination</text></passage><passage><infon key="fpage">73</infon><infon key="lpage">109</infon><infon key="name_0">surname:Xu;given-names:G</infon><infon key="name_1">surname:Jaffrey;given-names:SR</infon><infon key="pub-id_doi">10.5582/bst.2016.01033</infon><infon key="pub-id_pmid">24568254</infon><infon key="section_type">REF</infon><infon key="source">Biotechnology &amp; Genetic Engineering Reviews</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2013</infon><offset>47790</offset><text>Proteomic identification of protein ubiquitination events</text></passage><passage><infon key="fpage">509</infon><infon key="lpage">521</infon><infon key="name_0">surname:Zarain-Herzberg;given-names:A</infon><infon key="pub-id_doi">10.1139/y06-023</infon><infon key="pub-id_pmid">16902596</infon><infon key="section_type">REF</infon><infon key="source">Canadian Journal of Physiology and Pharmacology</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">2006</infon><offset>47848</offset><text>Regulation of the sarcoplasmic reticulum Ca2+-ATPase expression in the hypertrophic and failing heart</text></passage><passage><infon key="fpage">1012</infon><infon key="lpage">1019</infon><infon key="name_0">surname:Zhang;given-names:Y</infon><infon key="name_1">surname:Dedkov;given-names:EI</infon><infon key="name_2">surname:Lee;given-names:B;suffix:3rd</infon><infon key="name_3">surname:Li;given-names:Y</infon><infon key="name_4">surname:Pun;given-names:K</infon><infon key="name_5">surname:Gerdes;given-names:AM</infon><infon key="pub-id_doi">10.1016/j.cardfail.2014.10.003</infon><infon key="pub-id_pmid">25305503</infon><infon key="section_type">REF</infon><infon key="source">Journal of Cardiac Failure</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2014</infon><offset>47950</offset><text>Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model</text></passage><passage><infon key="fpage">12022</infon><infon key="lpage">12029</infon><infon key="name_0">surname:Zhao;given-names:TJ</infon><infon key="name_1">surname:Yan;given-names:YB</infon><infon key="name_2">surname:Liu;given-names:Y</infon><infon key="name_3">surname:Zhou;given-names:HM</infon><infon key="pub-id_doi">10.1016/j.bbapap.2008.08.018</infon><infon key="pub-id_pmid">17303563</infon><infon key="section_type">REF</infon><infon key="source">Journal of Biological Chemistry</infon><infon key="type">ref</infon><infon key="volume">282</infon><infon key="year">2007</infon><offset>48111</offset><text>The generation of the oxidized form of creatine kinase is a negative regulation on muscle creatine kinase</text></passage><passage><infon key="file">nihms859211f1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>48217</offset><text>MuRF1 inhibits T3-induced cardiomyocyte hypertrophy in vitro. (A) Confocal fluorescent images of HL-1 cardiomyocytes with MuRF1 gene knock-down (shMuRF1) in the presence and absence of T3 (16.6 nM). Gene-silencing controls (scrambled Adsh) were run in parallel. (B) Confocal image of HL-1 cells increased MuRF1 expression (AdMuRF1) treated with T3. GFP-transfected controls were included (AdGFP). (C) Primary neonatal rat ventricular myocytes (NRVM) with increased MuRF1 expression (AdMuRF1) and T3 treatment. Fluorescent confocal images show cell volume highlighted by GFP (green) and nuclear staining with DAPI (blue). Graphs contain quantitative analysis of cell area (&gt;= 200 cardiomyocytes averaged per group from three independent experiments). A two-way ANOVA test was used to determine statistical significance using a pairwise post-test and significance between groups is denoted by #P &lt; 0.05 or ##P &lt; 0.001. The F statistic and degrees of freedom (DF) were reported when dependence between groups was found to be a significant source of variation. *Significance at the level of adenovirus group, **Significance on the level of treatment group, 400x final magnification.</text></passage><passage><infon key="file">nihms859211f2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>49398</offset><text>MuRF1 inhibits TRalpha transcriptional activity following T3 treatment without affecting its steady-state levels. (A) TRE reporter assay results from Cos-7 cells co-transfected with luciferase plasmid containing TRE (or beta-galactosidase control), and FLAG-TRalpha plasmid, transduced with AdMuRF1 (4 h), then treated with 16.6 nM T3 for 24 h (n = 3 independent experiments). Immunoblot verifying FLAG-TRalpha and myc-MuRF1 protein expression shown below graph. (B) Relative expression of TR transcriptionally regulated genes; HL-1 cells were transfected with AdMuRF1 (or AdGFP control) for 24 h and then treated with T3 for 30 min (C) Immunoblot of endogenous TR protein expression following MuRF1 knock-down (shMuRF1) or increased MuRF1 expression (AdMuRF1) in HL-1 cardiomyocytes (beta-actin = loading control). Quantitative data shown in graphs below blots. Data are represented as mean +- S.E.M. (n = 3 independent experiments). A two-way ANOVA test was used to determine statistical significance. *Significance on the level of plasmid group. The F statistic and degrees of freedom (DF) were reported when dependence between groups was found to be a significant source of variation. Significance between groups is represented as #P &lt; 0.05 as determined using a pairwise post-test; n.s. = not significant.</text></passage><passage><infon key="file">nihms859211f3.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>50709</offset><text>MuRF1 increases TRalpha localization to nuclear region in cells treated with T3. HL-1 cardiomyocytes were transfected with FLAG-TRalpha plasmid transduced with AdMuRF1 (or AdGFP) and treated with 16.6 nM T3 for 2 h. (A) Confocal immunofluorescent images used to define TRalpha (anti-FLAG, red) and nuclei (DAPI, blue) co-localization. (B) Secondary-only fluorescence controls. Data are represented as mean +- S.E.M. (n = 3 independent experiments). For TRalpha/DAPI co-localization, a two-way ANOVA test was used to determine statistical significance. *Significance at the level of adenovirus group, **Significance on the level of treatment group. Significance between groups is represented as ##P &lt; 0.001 as determined using a pairwise post-test, 400x final magnification.</text></passage><passage><infon key="file">nihms859211f4.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>51483</offset><text>MuRF1 inhibits T3-induced TRalpha localization to the nuclear envelope (lamin beta1). HL-1 cardiomyocytes transfected with FLAG-TRalpha plasmid (empty FLAG = control), transduced with AdMuRF1 (AdGFP = control) for 4 h, and treated with 16.6 nM T3 for 2 h were assayed by confocal microscopy. (A) TRalpha (anti-FLAG, red) and endogenous lamin beta1 (green) co-localization at the nuclear membrane. A two-way ANOVA test was used to determine statistical significance. *Significance on the level of adenovirus group, **Significance on the level of treatment group. The F statistic and degrees of freedom (DF) were reported when dependence between groups was found to be a significant source of variation. Significance between groups is represented as #P &lt; 0.05, ##P &lt; 0.001, as determined using a pairwise post-test. (B) HL-1 cardiomyocytes were transduced with AdMuRF1 (24 h) and treated with 16.6 nM T3 (2 h) followed by fractionation. Immunoblot of endogenous TR and myc-MuRF1 after T3 treatment (p-Rb used as a loading control) in nuclear fraction. Data represent three independent experiments. A two-way ANOVA test was used to determine statistical significance with a pairwise post-test. *Significance on the level of adenovirus group, % Significant interaction between adenovirus and treatment groups, #Difference from treatment control group (criterion for cutoff; P &lt; 0.05). Data are presented as mean +- S.E.M., 400x final magnification.</text></passage><passage><infon key="file">nihms859211f5.jpg</infon><infon key="id">F5</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>52928</offset><text>MuRF1 interacts with and mono-ubiquitinates TRalpha. (A) Cos-7 cells transduced with AdMuRF1 and treated with 16.6 nM T3 for 2 h were used in analysis. Whole cell lysates were immunoprecipitated with myc-MuRF1 and probed for endogenous TRalpha to evaluate protein:protein interaction as shown in the blot (left). (B) GST-tagged recombinant peptides for each TR domain were used in an immunoprecipitation assay with myc-MuRF1 followed by immunoblot to establish the specific domain bound by MuRF1 (right). Blots shown on top right show the MuRF1-bound regions of TR (predominantly D); the top blot shows the bound myc-MuRF1 (eluate) for each domain construct. The middle blot shows unbound myc-MuRF1 and the bottom membrane is a Ponceau stain of each isolated peptide to confirm expression of the expected molecular weight protein (constructs were also sequenced to verify product, data not shown). At the far right is a diagram indicating the various domains, for reference. (C) An in vitro biochemical assay was used to assess ubiquitination with exogenous MuRF1 and was detected by immunoblot with HA-tagged Ub antibody. (D) Cos-7 cells co-transfected with HA-Ub and FLAG-TRalpha and transduced with AdMuRF1 (or AdGFP) at MOI 25 for 4 h; whole cell lysates were submitted to immunoprecipitation of FLAG-TRalpha followed by immunoblot for HA-Ub. The red box highlights ubiquitination in controls, whereas the blue box demonstrates the decrease in ubiquitination when MuRF1 expression is increased. Empty vector control (FLAG and HA) experiment blots are shown in left panel. (E) Diagram of TRalpha with known protein domains indicated in addition to the lysines within the E/F (ligand binding) domain with the corresponding (murine) amino acid sequence position (total of 15 residues). This region includes two lysines known to be targeted for regulation in the human isoform of TR for SUMOylation (K283 and K389).</text></passage><passage><infon key="file">nihms859211f6.jpg</infon><infon key="id">F6</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>54844</offset><text>MuRF1 inhibition of T3-induced cardiomyocyte hypertrophy is dependent on the centrosome-associated protein 350 (CAP350). (A) Confocal immunofluorescent images of TRalpha (anti-FLAG, red) and CAP350 (green) in cells transduced/transfected with vectors indicated and treated with T3 for 2 h (Fig. 3 for fluorescence controls). Data are reported as the mean +- S.E.M. (n = 3 independent experiments). A two-way ANOVA test was used to determine statistical significance. *Significance on the level of adenovirus group, **Significance on the level of treatment group. Significance between groups is represented as ##P &lt; 0.001 as determined using a pairwise post-test. (B) Knock down of CAP350 in HL1 cardiomyocytes using siRNA achieved &gt;50% reduction in protein by immunoblot analysis. (C) Cell cross-sectional area analysis of T3-stimulated HL-1 cells with increased MuRF1 (AdMuRF1) and CAP350 knock-down to identify the role of CAP350 in MuRF1-mediated inhibition of T3-induced hypertrophy. Data are reported as the mean +- S.E.M. (n = 2 independent experiments). A one-way ANOVA test was used to determine statistical significance. Significance between groups is represented as *P &lt; 0.05 vs all other groups, % P &lt; 0.05 vs groups 1, 4, and $P &lt; 0.05 in indicated comparisons, 400x final magnification.</text></passage><passage><infon key="file">nihms859211f7.jpg</infon><infon key="id">F7</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>56144</offset><text>MuRF1-mediated TRalpha nuclear accumulation following T3 treatment is dependent on TRalpha ligand-binding domain (E/F region) lysines. HL-1 cardiomyocytes were transfected with plasmids containing FLAG-TRalpha with various lysine to arginine (KR) mutants (Supplementary Fig. S2), transduced with AdMuRF1 for 4 h, and treated with 16.6 nM T3 for 2 h. (A) Nuclear localization of TRalpha was assessed using confocal immunofluorescent imaging of TRalpha (anti-FLAG, red) and nuclei (DAPI, blue). (B) MuRF1 (anti-myc, green) and TRalpha at the nucleus was assessed TRalpha (anti-FLAG, red). (C) TRalpha (anti-FLAG, red) and endogenous CAP350 (green). Data represent the mean +- S.E.M. A one-way ANOVA test was used to determine statistical significance. ##P &lt; 0.001 as determined by a pairwise post-test, 400x final magnification.</text></passage><passage><infon key="file">nihms859211f8.jpg</infon><infon key="id">F8</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>56971</offset><text>MuRF1's attenuation of TRalpha activity is identified in both MuRF1-/- and cardiac (alphaMHC)-MuRF1Tg+ mice in vivo after T3 stimulation. (A) Conscious echocardiographic data from wild-type (MuRF1+/+) and knockout (MuRF1-/-) receiving daily T3 i.p. (vehicle control = PBS) for 2 weeks (Table 1 for complete complementary echocardiographic data). (B) Gross and histological analysis of H&amp;E and Masson's trichrome hearts (100x magnification) from T3-treated MuRF1-/- mice. (C) Echocardiographic data from T3-treated wild-type MuRF1Tg+ and MuRF1Tg+ (Table 2 for complete complementary echocardiographic data). (D) Gross and histological analysis of H&amp;E and Masson's trichrome hearts (100x magnification) from T3-treated MuRF1Tg+ mice. A two-way ANOVA test was used to determine statistical significance using a pairwise post-test. For echocardiographic data:  P &lt; 0.001 vs all other groups, ***P &lt; 0.001 vs matched wild type, **P &lt; 0.001 vs MuRF1+/+ and MuRF1-/- baseline;  P &lt; 0.001 vs all other groups except MuRF1-/- +T3 at 2 weeks,   P &lt; 0.001 vs all other groups except MuRF1-/- +T3 at 1 week. Data on cardiomyocyte area were generated from three mice per group by averaging values from 400 cardiomyocytes per animal and statistical significance between indicated groups is designated by #P &lt; 0.05, ##P &lt; 0.001. The F statistic and degrees of freedom (DF) were reported when dependence between groups was found to be a significant source of variation, 20x final magnification.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>58482</offset><text>High-resolution trans-thoracic echocardiography performed on conscious MuRF1-/- and age-matched wild-type mice at baseline, 1 week, and 2 weeks after daily i.p. T3 treatment. Data represent means +- S.E.M. Groups were first analyzed with a one-way analysis of variance, and if significant, analyzed with a Holm-Sidak test for pairwise comparisons.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;
        &lt;thead&gt;
          &lt;tr&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;+/+ Baseline &lt;italic&gt;n&lt;/italic&gt; = 10&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;-/- Baseline &lt;italic&gt;n&lt;/italic&gt; = 12&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;+/+ Thyroid hormone 1 week &lt;italic&gt;n&lt;/italic&gt; = 10&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;-/- Thyroid hormone 1 week &lt;italic&gt;n&lt;/italic&gt; = 12&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;+/+ Thyroid hormone 2 weeks &lt;italic&gt;n&lt;/italic&gt; = 10&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;-/- Thyroid hormone 2 weeks &lt;italic&gt;n&lt;/italic&gt; = 12&lt;/th&gt;
          &lt;/tr&gt;
        &lt;/thead&gt;
        &lt;tbody&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LVEDD (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.03 +- 0.11&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.08 +- 0.12&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.13 +- 0.13&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.87 +- 0.15&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.11 +- 0.11&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.00 +- 0.14&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PWTD (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.97 +- 0.02&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.04 +- 0.04&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.12 +- 0.02&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.37 +- 0.07&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;,&lt;xref rid=&quot;TFN2&quot; ref-type=&quot;table-fn&quot;&gt;***&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.28 +- 0.05&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.58 +- 0.05&lt;xref rid=&quot;TFN1&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AWTS (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.77 +- 0.04&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.82 +- 0.06&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.97 +- 0.02&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.23 +- 0.08&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.23 +- 0.07&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.44 +- 0.06&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PWTS (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.58 +- 0.01&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.65 +- 0.07&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.81 +- 0.06&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.10 +- 0.08&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.93 +- 0.08&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.18 +- 0.07&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV Vol; d (L)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36.5 +- 3.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38.2 +- 3.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39.8 +- 3.7&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32.6 +- 3.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39.0 +- 3.4&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36.3 +- 4.1&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV Vol; s (L)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.8 +- 0.5&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.5 +- 0.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.8 +- 0.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.0 +- 0.5&lt;xref rid=&quot;TFN1&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.7 +- 1.0&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.0 +- 0.7&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV mass (mg)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;107.3 +- 6.1&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;124.8 +- 11.1&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;139.4 +- 7.6&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;187.8 +- 17.6&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;,&lt;xref rid=&quot;TFN2&quot; ref-type=&quot;table-fn&quot;&gt;***&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;170.3 +- 8.8&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;237.4 +- 19.8&lt;xref rid=&quot;TFN1&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV mass/BW (mg/g)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.1 +- 0.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.7 +- 0.2&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.2 +- 0.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.4 +- 0.2&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;,&lt;xref rid=&quot;TFN2&quot; ref-type=&quot;table-fn&quot;&gt;***&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.9 +- 0.3&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.0 +- 0.2&lt;xref rid=&quot;TFN1&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BW (g)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26.1 +- 0.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26.7 +- 2.5&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27.3 +- 0.7&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.0 +- 1.9&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28.9 +- 1.1&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.5 +- 1.8&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HR (bpm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;665 +- 9&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;670 +- 13&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;708 +- 21&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;727 +- 11&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;730 +- 14&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;729 +- 10&lt;xref rid=&quot;TFN3&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
        &lt;/tbody&gt;
      &lt;/table&gt;
</infon><offset>58836</offset><text>	MuRF1+/+ Baseline n = 10	MuRF1-/- Baseline n = 12	MuRF1+/+ Thyroid hormone 1 week n = 10	MuRF1-/- Thyroid hormone 1 week n = 12	MuRF1+/+ Thyroid hormone 2 weeks n = 10	MuRF1-/- Thyroid hormone 2 weeks n = 12	 	LVEDD (mm)	3.03 +- 0.11	3.08 +- 0.12	3.13 +- 0.13	3.87 +- 0.15	3.11 +- 0.11	3.00 +- 0.14	 	PWTD (mm)	0.97 +- 0.02	1.04 +- 0.04	1.12 +- 0.02**	1.37 +- 0.07**,***	1.28 +- 0.05	1.58 +- 0.05 	 	AWTS (mm)	1.77 +- 0.04	1.82 +- 0.06	1.97 +- 0.02	2.23 +- 0.08	2.23 +- 0.07	2.44 +- 0.06	 	PWTS (mm)	1.58 +- 0.01	1.65 +- 0.07	1.81 +- 0.06	2.10 +- 0.08	1.93 +- 0.08	2.18 +- 0.07	 	LV Vol; d (L)	36.5 +- 3.3	38.2 +- 3.8	39.8 +- 3.7	32.6 +- 3.8	39.0 +- 3.4	36.3 +- 4.1	 	LV Vol; s (L)	4.8 +- 0.5	5.5 +- 0.8	5.8 +- 0.8	3.0 +- 0.5 	5.7 +- 1.0	4.0 +- 0.7	 	LV mass (mg)	107.3 +- 6.1	124.8 +- 11.1	139.4 +- 7.6	187.8 +- 17.6**,***	170.3 +- 8.8**	237.4 +- 19.8 	 	LV mass/BW (mg/g)	4.1 +- 0.3	4.7 +- 0.2	5.2 +- 0.3	6.4 +- 0.2**,***	5.9 +- 0.3**	8.0 +- 0.2 	 	BW (g)	26.1 +- 0.8	26.7 +- 2.5	27.3 +- 0.7	29.0 +- 1.9	28.9 +- 1.1	29.5 +- 1.8	 	HR (bpm)	665 +- 9	670 +- 13	708 +- 21	727 +- 11**	730 +- 14**	729 +- 10**	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>59966</offset><text>P &lt; 0.001 vs all other groups.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>59997</offset><text>P &lt; 0.001 vs matched wild type.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>60029</offset><text>P &lt; 0.001 vs MuRF1+/+ and MuRF1-/- baseline.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>60078</offset><text>P &lt; 0.001 vs all other groups except MuRF1-/- with T3 at 2 weeks.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>60148</offset><text>P &lt; 0.001 vs all other groups except MuRF1-/- with T3 at 1 week. HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, calculated as (LVEDD-LVESD)/LVEDD x100; EF%, ejection fraction calculated as (end Simpson's diastolic volume - end Simpson's systolic volume)/end Simpson's diastolic volume x100, ND, not determined</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>60811</offset><text>High-resolution trans-thoracic echocardiography performed on conscious MuRF1Tg+ and age-matched wild-type mice at baseline, 1 week, and 2 weeks after daily i.p. T3 treatment. Data represent means +- S.E.M. Groups were first analyzed with a one-way ANOVA, and if significant, analyzed with a Holm-Sidak test for pairwise comparisons.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;
        &lt;thead&gt;
          &lt;tr&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1Tg&lt;/italic&gt;&lt;sup&gt;+&lt;/sup&gt; Wild type Baseline &lt;italic&gt;n&lt;/italic&gt; = 16&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;Tg&lt;sup&gt;+&lt;/sup&gt; Baseline &lt;italic&gt;n&lt;/italic&gt; = 11&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;Tg&lt;sup&gt;+&lt;/sup&gt; wild type Thyroid hormone 1 week &lt;italic&gt;n&lt;/italic&gt; = 16&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;Tg&lt;sup&gt;+&lt;/sup&gt; Thyroid hormone 1 week &lt;italic&gt;n&lt;/italic&gt; = 10&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;Tg&lt;sup&gt;+&lt;/sup&gt; wild type Thyroid hormone 2 weeks &lt;italic&gt;n&lt;/italic&gt; = 16&lt;/th&gt;
            &lt;th valign=&quot;middle&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;MuRF1&lt;/italic&gt;Tg&lt;sup&gt;+&lt;/sup&gt; Thyroid hormone 2 weeks &lt;italic&gt;n&lt;/italic&gt; = 11&lt;/th&gt;
          &lt;/tr&gt;
        &lt;/thead&gt;
        &lt;tbody&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PWTD (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.02 +- 0.02&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.96 +- 0.02&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.15 +- 0.10&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.27 +- 0.11&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.20 +- 0.11&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.54 +- 0.13&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AWTS (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.70 +- 0.05&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.54 +- 0.06&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.48 +- 0.07&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN8&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.80 +- 0.09&lt;xref rid=&quot;TFN9&quot; ref-type=&quot;table-fn&quot;&gt;***&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.64 +- 0.10&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN7&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.23 +- 0.14&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LVESD (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.53 +- 0.07&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.88 +- 0.14&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.36 +- 0.06&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.18 +- 0.12&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.41 +- 0.04&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.11 +- 0.03&lt;xref rid=&quot;TFN7&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PWTS (mm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.58 +- 0.04&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.33 +- 0.06&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.86 +- 0.05&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.60 +- 0.03&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.92 +- 0.05&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN11&quot; ref-type=&quot;table-fn&quot;&gt;  &lt;/xref&gt;,&lt;xref rid=&quot;TFN7&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.50 +- 0.06&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV Vol; d (L)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37.4 +- 2.4&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41.6 +- 4.6&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;40.3 +- 3.0&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44.1 +- 3.7&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42.1 +- 3.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53.4 +- 4.6&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV Vol; s (L)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.8 +- 0.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.0 +- 2.1&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.3 +- 0.9&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.4 +- 1.1&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.5 +- 1.4&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17.9 +- 2.4&lt;xref rid=&quot;TFN6&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN11&quot; ref-type=&quot;table-fn&quot;&gt;  &lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV mass (mg)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;116.6 +- 7.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;107.4 +- 9.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;178.5 +- 8.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;137.7 +- 7.4&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;201.8 +- 110.8&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN11&quot; ref-type=&quot;table-fn&quot;&gt;  &lt;/xref&gt;,&lt;xref rid=&quot;TFN8&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;155.0 +- 10.2&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LV mass/BW (mg/g)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.1 +- 0.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.1 +- 0.7&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.2 +- 0.2&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.2 +- 0.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.7 +- 0.2&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;,&lt;xref rid=&quot;TFN11&quot; ref-type=&quot;table-fn&quot;&gt;  &lt;/xref&gt;,&lt;xref rid=&quot;TFN8&quot; ref-type=&quot;table-fn&quot;&gt;**&lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.5 +- 0.3&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BW (g)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.3 +- 1.3&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27.7 +- 1.8&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.9 +- 1.1&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26.9 +- 1.5&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.8 +- 0.9&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28.1 +- 1.1&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HR (bpm)&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;711 +- 13&lt;xref rid=&quot;TFN11&quot; ref-type=&quot;table-fn&quot;&gt;  &lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;679 +- 10&lt;xref rid=&quot;TFN11&quot; ref-type=&quot;table-fn&quot;&gt;  &lt;/xref&gt;&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;802 +- 9&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;802 +- 7&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;798 +- 13&lt;/td&gt;
            &lt;td align=&quot;center&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;768 +- 6&lt;xref rid=&quot;TFN10&quot; ref-type=&quot;table-fn&quot;&gt; &lt;/xref&gt;&lt;/td&gt;
          &lt;/tr&gt;
        &lt;/tbody&gt;
      &lt;/table&gt;
</infon><offset>61146</offset><text>	MuRF1Tg+ Wild type Baseline n = 16	MuRF1Tg+ Baseline n = 11	MuRF1Tg+ wild type Thyroid hormone 1 week n = 16	MuRF1Tg+ Thyroid hormone 1 week n = 10	MuRF1Tg+ wild type Thyroid hormone 2 weeks n = 16	MuRF1Tg+ Thyroid hormone 2 weeks n = 11	 	PWTD (mm)	1.02 +- 0.02	0.96 +- 0.02	3.15 +- 0.10	3.27 +- 0.11	3.20 +- 0.11	3.54 +- 0.13	 	AWTS (mm)	1.70 +- 0.05	1.54 +- 0.06	1.48 +- 0.07 , ,**	1.80 +- 0.09***	1.64 +- 0.10 ,*	2.23 +- 0.14	 	LVESD (mm)	1.53 +- 0.07	1.88 +- 0.14	1.36 +- 0.06	1.18 +- 0.12	1.41 +- 0.04	1.11 +- 0.03*	 	PWTS (mm)	1.58 +- 0.04	1.33 +- 0.06	1.86 +- 0.05 	1.60 +- 0.03	1.92 +- 0.05 ,  ,*	1.50 +- 0.06	 	LV Vol; d (L)	37.4 +- 2.4	41.6 +- 4.6	40.3 +- 3.0	44.1 +- 3.7	42.1 +- 3.3	53.4 +- 4.6	 	LV Vol; s (L)	6.8 +- 0.8	12.0 +- 2.1	6.3 +- 0.9	10.4 +- 1.1	8.5 +- 1.4	17.9 +- 2.4 , ,  	 	LV mass (mg)	116.6 +- 7.3	107.4 +- 9.3	178.5 +- 8.3	137.7 +- 7.4	201.8 +- 110.8 ,  ,**	155.0 +- 10.2	 	LV mass/BW (mg/g)	4.1 +- 0.3	5.1 +- 0.7	6.2 +- 0.2 	5.2 +- 0.3	6.7 +- 0.2 ,  ,**	5.5 +- 0.3	 	BW (g)	29.3 +- 1.3	27.7 +- 1.8	29.9 +- 1.1	26.9 +- 1.5	29.8 +- 0.9	28.1 +- 1.1	 	HR (bpm)	711 +- 13  	679 +- 10  	802 +- 9	802 +- 7	798 +- 13	768 +- 6 	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>62323</offset><text>P &lt; 0.001 vs all other wild-type groups.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>62364</offset><text>P &lt; 0.001 vs matched wild type.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>62396</offset><text>P &lt; 0.001 vs MuRF1Tg+ 2 weeks after T3 treatment.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>62446</offset><text>P &lt; 0.001 vs MuRF1Tg+ baseline.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>62478</offset><text>P &lt; 0.001 vs baseline groups</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>62507</offset><text>P &lt; 0.001 vs 1 week T3 groups. HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, calculated as (LVEDD-LVESD)/LVEDD x100; EF%, ejection fraction calculated as (end Simpson's diastolic volume - end Simpson's systolic volume)/end Simpson's diastolic volume x100, ND, not determined</text></passage></document>
</collection>